• Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
    • Berchuck A, Secord AA, Moss HA, Havrilesky LJ.
    • J Clin Oncol. 2017 Dec 20;35(36):3999-4002. doi: 10.1200/JCO.2017.74.5752. Epub 2017 Oct 26.
    • BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
    • Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R.
    • Cell Rep. 2017 Dec 19;21(12):3398-3405. doi: 10.1016/j.celrep.2017.11.095.
    • Emerging treatment options for ovarian cancer: focus on rucaparib.
    • Mariappan L, Jiang XY, Jackson J, Drew Y.
    • Int J Womens Health. 2017 Dec 15;9:913-924. doi: 10.2147/IJWH.S151194. eCollection 2017.
    • Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists.
    • Audibert C, Perlaky A, Stuntz M, Glass D.
    • Drug Des Devel Ther. 2017 Dec 6;11:3471-3479. doi: 10.2147/DDDT.S151420. eCollection 2017.
    • The OlympiAD trial: who won the gold?
    • Gyawali B.
    • Ecancermedicalscience. 2017 Dec 6;11:ed75. doi: 10.3332/ecancer.2017.ed75. eCollection 2017.
    • FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer.
    • Balasubramaniam S, Beaver JA, Horton S, Fernandes LL, Tang S, Horne HN, Liu J, Liu C, Schrieber SJ, Yu J, Song P, Pierce W, Robertson KJ, Palmby TR, Chiu HJ, Lee EY, Philip R, Schuck R, Charlab R, Banerjee A, Chen XH, Wang X, Goldberg KB, Sridhara R, Kim G, Pazdur R.
    • Clin Cancer Res. 2017 Dec 1;23(23):7165-7170. doi: 10.1158/1078-0432.CCR-17-1337. Epub 2017 Jul 27.
    • Summary
    • Changes in gene expression variability reveal a stable synthetic lethal interaction network in BRCA2-ovarian cancers.
    • Bueno R, Mar JC.
    • Methods. 2017 Dec 1;131:74-82. doi: 10.1016/j.ymeth.2017.07.021. Epub 2017 Jul 25.
    • Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
    • Dockery LE, Tew WP, Ding K, Moore KN.
    • Gynecol Oncol. 2017 Dec;147(3):509-513. doi: 10.1016/j.ygyno.2017.10.007. Epub 2017 Oct 14.
    • PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
    • Bitler BG, Watson ZL, Wheeler LJ, Behbakht K.
    • Gynecol Oncol. 2017 Dec;147(3):695-704. doi: 10.1016/j.ygyno.2017.10.003. Epub 2017 Oct 14.
    • PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.
    • Sisay M, Edessa D.
    • Gynecol Oncol Res Pract. 2017 Nov 29;4:18. doi: 10.1186/s40661-017-0055-8. eCollection 2017.
    • High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.
    • Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA.
    • Oncotarget. 2017 Nov 6;8(61):104430-104443. doi: 10.18632/oncotarget.22303. eCollection 2017 Nov 28.
    • Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer.
    • Ratajska M, Koczkowska M, Żuk M, Gorczyński A, Kuźniacka A, Stukan M, Biernat W, Limon J, Wasąg B.
    • Oncotarget. 2017 Sep 8;8(60):101325-101332. doi: 10.18632/oncotarget.20722. eCollection 2017 Nov 24.
    • The roles of pathology in targeted therapy of women with gynecologic cancers.
    • Murali R, Grisham RN, Soslow RA.
    • Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31530-5. doi: 10.1016/j.ygyno.2017.11.020. [Epub ahead of print]
    • Review
    • Increased single-strand annealing rather than non-homologous end-joining predicts hereditary ovarian carcinoma.
    • Deniz M, Romashova T, Kostezka S, Faul A, Gundelach T, Moreno-Villanueva M, Janni W, Friedl TWP, Wiesmüller L.
    • Oncotarget. 2017 Oct 9;8(58):98660-98676. doi: 10.18632/oncotarget.21720. eCollection 2017 Nov 17.
    • Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer.
    • Wang Y, Ung MH, Cantor S, Cheng C.
    • Sci Rep. 2017 Nov 16;7(1):15742. doi: 10.1038/s41598-017-16138-2.
    • Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer.
    • Garber J.
    • OncoTherapy Network. 2017 Nov 15.
    • BRCA mutations in the manifestation and treatment of ovarian cancer.
    • Pan Z, Xie X.
    • Oncotarget. 2017 May 30;8(57):97657-97670. doi: 10.18632/oncotarget.18280. eCollection 2017 Nov 14.
    • Checkpoint and PARP inhibitors, for whom and when.
    • Lee JM, Gulley JL.
    • Oncotarget. 2017 Sep 12;8(56):95036-95037. doi: 10.18632/oncotarget.20852. eCollection 2017 Nov 10.
    • 'Important' Progress in Gynecologic Cancers: ESMO 2017.
    • Susana Banerjee
    • Medscape. News & Perspective. 2017 Nov 3.
    • Treatment of recurrent ovarian cancer.
    • Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F.
    • Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56. doi: 10.1093/annonc/mdx441.
    • Review, Conference abstract
    • Differential toxicity in patients with and without DNA repair mutations: Phase I Study of Carboplatin and Talazoparib in advanced solid tumors.
    • Dhawan MS, Bartelink IH, Aggarwal R, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser MM, Kelley RK, Maktabi T, Thomas S, Munster PN.
    • Clin Cancer Res. 2017 Nov 1;23(21):6400-6410. doi: 10.1158/1078-0432.CCR-17-0703. Epub 2017 Aug 8.
    • Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
    • Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, Garcia-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J1, Reis-Filho JS, Greenberg RA, Robson M, Turner NC.
    • Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1.
    • Treatment of recurrent ovarian cancer.
    • Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F.
    • Ann Oncol. 2017 Nov;28 Suppl 8:viii51-viii56. doi: 10.1093/annonc/mdx441.
    • Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
    • Gadducci A, Guerrieri ME.
    • Anticancer Res. 2017 Nov;37(11):5955-5965.
    • Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.
    • Kawahara N, Ogawa K, Nagayasu M, Kimura M, Sasaki Y, Kobayashi H.
    • Biomed Rep. 2017 Nov;7(5):391-399. doi: 10.3892/br.2017.990. Epub 2017 Sep 27.
    • [Abnormalities of DNA repair and gynecological cancers].
    • Auguste A, Leary A.
    • Bull Cancer. 2017 Nov;104(11):971-980. doi: 10.1016/j.bulcan.2017.09.007. Epub 2017 Oct 18.
    • Review, [Article in French]
    • [DNA repair as a therapeutic target].
    • Eberst L, Brahmi M, Cassier PA.
    • Bull Cancer. 2017 Nov;104(11):988-998. doi: 10.1016/j.bulcan.2017.09.005. Epub 2017 Nov 11.
    • Review, [Article in French]
    • Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.
    • Hoskins PJ, Gotlieb WH.
    • CA Cancer J Clin. 2017 Nov;67(6):493-506. doi: 10.3322/caac.21408. Epub 2017 Sep 7.
    • Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.
    • Trafalis DT, Polonifi A, Dalezis P, Nikoleousakos N, Katsamakas S, Sarli V.
    • Chem Biol Drug Des. 2017 Nov;90(5):854-866. doi: 10.1111/cbdd.13006. Epub 2017 May 26.
    • Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
    • Vanderstichele A, Busschaert P, Olbrecht S, Lambrechts D, Vergote I.
    • Eur J Cancer. 2017 Nov;86:5-14. doi: 10.1016/j.ejca.2017.08.029. Epub 2017 Sep 23.
    • Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
    • Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS.
    • Gynecol Oncol. 2017 Nov;147(2):267-275. doi: 10.1016/j.ygyno.2017.08.022. Epub 2017 Sep 4.
    • Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study.
    • Steffensen KD, Adimi P, Jakobsen A.
    • Int J Gynecol Cancer. 2017 Nov;27(9):1842-1849. doi: 10.1097/IGC.0000000000001089.
    • Novel Therapeutics for Ovarian Cancer: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    • Johnson N, Liao JB.
    • Int J Gynecol Cancer. 2017 Nov;27(9S Suppl 5):S14-S19. doi: 10.1097/IGC.0000000000001115.
    • Conference report
    • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    • Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators.
    • Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12.

    Comment:

    PARP inhibitors for targeted treatment in ovarian cancer.

    • Mitigating Side Effects to Reach PARP Inhibitors' Potential.
    • Markman M.
    • Medscape. News & Perspective. 2017 Oct 13.
    • Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.
    • Thomas SN, Chen L, Liu Y, Hoti N, Zhang H.
    • J Proteome Res. 2017 Oct 6;16(10):3704-3710. doi: 10.1021/acs.jproteome.7b00405. Epub 2017 Sep 14.
    • The HRD decision--which PARP inhibitor to use for whom and when.
    • Kohn EC, Lee JM, Ivy SP.
    • Clin Cancer Res. 2017 Oct 3. doi: 10.1158/1078-0432.CCR-17-2186. [Epub ahead of print]
    • Revew
    • ARIEL4: An international, randomised phase 3 study of rucaparib vs chemotherapy as treatment for BRCA1- or BRCA2-mutated, relapsed ovarian cancer.
    • Lorusso D, Nicoletta C, Sandro P, Roberto S, Paolo , Claudio , Amit MO, Ana O, Tamar S, Elizabeth MS, Igor MB, Tomasz H, Jaroslav K, Vladimir M, Róbert P, Luciana SV, Chris T, Caro U, Adam D, Rebecca SK.
    • Ann Oncol. 2017 Oct;28 Suppl 6:vi71. doi: 10.1093/annonc/mdx429.004.
    • Retrospective analysis of 77 patients with ovarian cancer undergoing genetic testing for BRCA1 and BRCA2 mutations.
    • Tavella K, Villanucci A, Vannini L, Rossi V, Fantechi B, Capone G, Putignano AL, Gensini F, Porfirio B, Amunni G, Mazzei T, Mini E, Papi L.
    • Ann Oncol. 2017 Oct;28 Suppl 6:vi71. doi: 10.1093/annonc/mdx429.005.
    • Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice.
    • González-Martín A.
    • Future Oncol. 2017 Oct;13(23s):3-9. doi: 10.2217/fon-2017-0316. Epub 2017 Oct 11.
    • Review, Conference report
    • Trabectedin mechanism of action and platinum resistance: molecular rationale.
    • Ray-Coquard I.
    • Future Oncol. 2017 Oct;13(23s):17-21. doi: 10.2217/fon-2017-0318. Epub 2017 Oct 11.
    • Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
    • van Haaften C, van Eendenburg J, Boot A, Corver WE, Haans L, van Wezel T, Trimbos JB.
    • Int J Gynecol Cancer. 2017 Oct;27(8):1571-1578. doi: 10.1097/IGC.0000000000001052.
    • BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.
    • Paculová H, Kramara J, Šimečková Š, Fedr R, Souček K, Hylse O, Paruch K, Svoboda M, Mistrík M, Kohoutek J.
    • Tumour Biol. 2017 Oct;39(10):1010428317727479. doi: 10.1177/1010428317727479.
    • The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation.
    • Strumidło A, Skiba S, Scott RJ, Lubiński J.
    • Hered Cancer Clin Pract. 2017 Sep 29;15:15. doi: 10.1186/s13053-017-0076-7. eCollection 2017.
    • Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer.
    • Prieske K, Prieske S, Joosse SA, Trillsch F, Grimm D, Burandt E, Mahner S, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L, Woelber L.
    • Oncotarget. 2017 Sep 15;8(47):83063-83074. doi: 10.18632/oncotarget.20945. eCollection 2017 Oct 10.
    • Checkpoint and PARP inhibitors, for whom and when.
    • Lee JM, Gulley JL.
    • Oncotarget. 2017 Sep 12. doi: 10.18632/oncotarget.20852. [Epub ahead of print]
    • Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
    • Herzog TJ, Monk BJ.
    • Gynecol Oncol Res Pract. 2017 Sep 7;4:13. doi: 10.1186/s40661-017-0050-0. eCollection 2017.
    • BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    • Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, Benedetti Panici P, Scambia G, Fagotti A.
    • Am J Obstet Gynecol. 2017 Sep;217(3):334.e1-334.e9. doi: 10.1016/j.ajog.2017.05.036. Epub 2017 May 23.
    • Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-grade Ovarian Carcinoma.
    • Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza AM, Sun JX, Robillard L, Maloney L, Bowtell DDL, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin K, Scott CL.
    • Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

    Review:

    Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.

    • An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    • Chung C, Lee R.
    • J Oncol Pharm Pract. 2017 Sep;23(6):454-469. doi: 10.1177/1078155216657165. Epub 2016 Jun 29.
    • Review
    • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
    • Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators.
    • Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25.

    Research report, Comment:

    To promote maintenance or treatment, is that the question?

    Press: Olaparib Prolongs Progression-Free Survival in Relapsed Ovarian Cancer. (Medscape/Reuters)

    • Niraparib in ovarian cancer: results to date and clinical potential.
    • Caruso D, Papa A, Tomao S, Vici P, Panici PB, Tomao F.
    • Ther Adv Med Oncol. 2017 Sep;9(9):579-588. doi: 10.1177/1758834017718775. Epub 2017 Jul 12.
    • FDA Approves New Indication and Formulation for Olaparib.
    • Nelson R.
    • Medscape. 2017 Aug 17.
    • Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma.
    • Rivera B, Di Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, Burk DL, Grapton D, Tomiak E, Hastings V, Hamel N, Wagener R, Aleynikova O, Giroux S, Hamdan FF, Dionne-Laporte A, Zogopoulos G, Rousseau F, Berghuis AM, Provencher D, Rouleau GA, Michaud JL, Mes-Masson AM, Majewski J, Bens S, Siebert R, Narod SA, Akbari MR, Lord CJ, Tonin PN, Orthwein A, Foulkes WD.
    • Cancer Res. 2017 Aug 15;77(16):4517-4529. doi: 10.1158/0008-5472.CAN-17-0190. Epub 2017 Jun 23.
    • Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
    • Yuan Z, Chen S, Sun Q, Wang N, Li D, Miao S, Gao C, Chen Y, Tan C, Jiang Y.
    • Bioorg Med Chem. 2017 Aug 1;25(15):4100-4109. doi: 10.1016/j.bmc.2017.05.058. Epub 2017 May 31.
    • Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    • Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson D, Timms KM, Lanchbury JS, Kaye SB, Gourley C, Bowtell DD, Kohn EC, Scott CL, Matulonis UA, Panzarella T, Karakasis K, Burnier JV, Gilks B, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM.
    • Clin Cancer Res. 2017 Aug 1;23(15):4086-4094. doi: 10.1158/1078-0432.CCR-16-2615. Epub 2017 Feb 21.
    • A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.
    • Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso PM, Patel M, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R.
    • Clin Cancer Res. 2017 Aug 1;23(15):4095-4106. doi: 10.1158/1078-0432.CCR-16-2796. Epub 2017 Mar 6.
    • Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells.
    • Do TV, Hirst J, Hyter S, Roby KF, Godwin AK.
    • Oncotarget. 2017 Jul 5;8(31):50376-50392. doi: 10.18632/oncotarget.18970. eCollection 2017 Aug 1.
    • A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
    • Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, Lu KH.
    • Gynecol Oncol. 2017 Aug;146(2):399-404. doi: 10.1016/j.ygyno.2017.05.037. Epub 2017 Jun 10.
    • Malignant Brenner tumor associated with a germline BRCA2 mutation.
    • Toboni MD, Smith HJ, Dilley SE, Novak L, Leath CA.
    • Gynecol Oncol Rep. 2017 May 31;21:17-19. doi: 10.1016/j.gore.2017.05.006. eCollection 2017 Aug.
    • Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
    • Oda K, Tanikawa M, Sone K, Mori-Uchino M, Osuga Y, Fujii T.
    • Int J Clin Oncol. 2017 Aug;22(4):611-618. doi: 10.1007/s10147-017-1137-7. Epub 2017 May 15.
    • Review
    • Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    • Murai J.
    • Int J Clin Oncol. 2017 Aug;22(4):619-628. doi: 10.1007/s10147-017-1145-7. Epub 2017 Jun 22.
    • Review
    • BRCA mutation in ovarian cancer: testing, implications and treatment considerations.
    • Neff RT, Senter L, Salani R.
    • Ther Adv Med Oncol. 2017 Aug;9(8):519-531. doi: 10.1177/1758834017714993. Epub 2017 Jun 19.
    • Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma.
    • Conroy M, Borad MJ, Bryce AH.
    • Cureus. 2017 Jul 26;9(7):e1517. doi: 10.7759/cureus.1517.
    • Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
    • Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L.
    • Sci Transl Med. 2017 Jul 26;9(400). pii: eaal1645. doi: 10.1126/scitranslmed.aal1645.
    • Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    • Rafii S, Gourley C, Kumar R, Geuna E, Ang JE, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.
    • Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.
    • Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
    • Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, Yelensky R, Spencer SK, Robertson JD, Ho TW, Fielding A, Ledermann JA, Barrett JC.
    • Oncotarget. 2017 Jul 4;8(27):43653-43661. doi: 10.18632/oncotarget.17613.

    Research news:

    Olaparib and somatic BRCA mutations.

    • Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
    • Sokolenko AP, Savonevich EL, Ivantsov AO, Raskin GA, Kuligina ES, Gorodnova TV, Preobrazhenskaya EV, Kleshchov MA, Tyurin VI, Mukhina MS, Kotiv KB, Shulga AV, Kuznetsov SG, Berlev IV, Imyanitov EN.
    • Cancer Lett. 2017 Jul 1;397:127-132. doi: 10.1016/j.canlet.2017.03.036. Epub 2017 Apr 1.
    • Development of PARP inhibitors in gynecological malignancies.
    • Ang YLE, Tan DSP.
    • Curr Probl Cancer. 2017 Jul - Aug;41(4):273-286. doi: 10.1016/j.currproblcancer.2017.02.008. Epub 2017 Mar 14.
    • Review
    • Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.
    • Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD.
    • Cancer Chemother Pharmacol. 2017 Jul;80(1):165-175. doi: 10.1007/s00280-017-3346-1. Epub 2017 Jun 2.
    • Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma.
    • Graybill WS, Pothuri B, Chase DM, Monk BJ.
    • Gynecol Oncol. 2017 Jul;146(1):11-15. doi: 10.1016/j.ygyno.2017.03.508. Epub 2017 Apr 6.
    • Editorial, Commentary
    • Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
    • Bookman MA, Tyczynski JE, Espirito JL, Wilson TW, Fernandes AW.
    • Gynecol Oncol. 2017 Jul;146(1):58-63. doi: 10.1016/j.ygyno.2017.04.011. Epub 2017 Apr 26.
    • Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    • Zhao Q, Yang J, Li L, Cao D, Yu M, Shen K; BGI Group.
    • J Gynecol Oncol. 2017 Jul;28(4):e39. doi: 10.3802/jgo.2017.28.e39.
    • Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.
    • Balendran S, Liebmann-Reindl S, Berghoff AS, Reischer T, Popitsch N, Geier CB, Kenner L, Birner P, Streubel B, Preusser M.
    • J Neurooncol. 2017 Jul;133(3):469-476. doi: 10.1007/s11060-017-2459-z. Epub 2017 May 11.
    • Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.
    • Dockery LE, Gunderson CC, Moore KN.
    • Onco Targets Ther. 2017 Jun 19;10:3029-3037. doi: 10.2147/OTT.S114714. eCollection 2017.
    • Acquired cross-linker resistance associated with a novel spliced BRCA2 protein variant for molecular phenotyping of BRCA2 disruption.
    • Meyer S, Stevens A, Paredes R, Schneider M, Walker MJ, Williamson AJK, Gonzalez-Sanchez MB, Smetsers S, Dalal V, Teng HY, White DJ, Taylor S, Muter J, Pierce A, de Leonibus C, Rockx DAP, Rooimans MA, Spooncer E, Stauffer S, Biswas K, Godthelp B, Dorsman J, Clayton PE, Sharan SK, Whetton AD.
    • Cell Death Dis. 2017 Jun 15;8(6):e2875. doi: 10.1038/cddis.2017.264.
    • Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models.
    • Kim H, George E, Ragland RL, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown EJ, Simpkins F.
    • Clin Cancer Res. 2017 Jun 15;23(12):3097-3108. doi: 10.1158/1078-0432.CCR-16-2273. Epub 2016 Dec 19.
    • OlympiAD: Olaparib Captures Gold for BRCA-Mutated Breast Cancer Patients.
    • Miller KD, Domchek SM.
    • Medscape. Coverage from the ASCO 2017 Annual Meeting. 2017 Jun 12.
    • Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
    • Cuyàs E, Martin-Castillo B, Bosch-Barrera J, Menendez JA.
    • Cell Cycle. 2017 Jun 3;16(11):1022-1028. doi: 10.1080/15384101.2017.1310353. Epub 2017 Apr 7.
    • Whence High-Grade Serous Ovarian Cancer.
    • Kohn EC, Ivy SP.
    • Am Soc Clin Oncol Educ Book. [Presented Friday, June 2, 2017.] 2017;37:443-448. doi: 10.14694/EDBK_174718.
    • Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
    • de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA.
    • Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27.
    • PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
    • Gadducci A, Guerrieri ME.
    • Crit Rev Oncol Hematol. 2017 Jun;114:153-165. doi: 10.1016/j.critrevonc.2017.04.006. Epub 2017 Apr 20.

    Commentary: 'Clear Role' for PARP Inhibitors in Advanced Ovarian Cancer. (Medscape Oncology)

    • Niraparib: First Global Approval.
    • Scott LJ.
    • Drugs. 2017 Jun;77(9):1029-1034. doi: 10.1007/s40265-017-0752-y.
    • Review
    • Therapeutic targeting and patient selection for cancers with homologous recombination defects.
    • Talens F, Jalving M, Gietema JA, van Vugt MATM.
    • Expert Opin Drug Discov. 2017 Jun;12(6):565-581. doi: 10.1080/17460441.2017.1322061. Epub 2017 May 2.
    • The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.
    • Lorusso D, Fontanella C, Maltese G, Lepori S, Tripodi E, Bogani G, Raspagliesi F.
    • Expert Opin Drug Saf. 2017 Jun;16(6):687-696. doi: 10.1080/14740338.2017.1325871. Epub 2017 May 18.
    • Review
    • [Il ruolo di niraparib nel trattamento del carcinoma ovarico: attualità e prospettive.] [The role of niraparib in the treatment of ovarian cancer: actuality and perspectives]
    • Sabatucci I, Lorusso D.
    • Recenti Prog Med. 2017 Jun;108(6):265-268. doi: 10.1701/2715.27713.
    • Review, [Article in Italian]
    • [Innovations in the treatment of ovarian cancer. Analysis of the therapeutic development: from platinum to immunotherapy.]
    • Angius G, Sepe P, Papa A, Tomao S, Tomao F.
    • Recenti Prog Med. 2017 Jun;108(6):269-281. doi: 10.1701/2715.27714.
    • Review, [Article in Italian]
    • Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.
    • Capoluongo E, Ellison G, López-Guerrero JA, Penault-Llorca F, Ligtenberg MJL, Banerjee S, Singer C, Friedman E, Markiefka B, Schirmacher P, Büttner R, van Asperen CJ, Ray-Coquard I, Endris V, Kamel-Reid S, Percival N, Bryce J, Röthlisberger B, Soong R, de Castro DG.
    • Semin Oncol. 2017 Jun;44(3):187-197. doi: 10.1053/j.seminoncol.2017.08.004. Epub 2017 Sep 15.
    • Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.
    • Di Napoli M, Della Pepa C, Arenare L, Scambia G, Lorusso D, Raspagliesi F, Ferrandina G, Salutari V, Sorio R, Mosconi AM, Mangili G, Borgato L, Lepori S, Salvino A, Pignata S, Cecere SC.
    • Support Care Cancer. 2017 Jun;25(6):1743-1748. doi: 10.1007/s00520-016-3547-x. Epub 2017 Jan 19.
    • Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.
    • Hollis RL, Churchman M, Gourley C.
    • Onco Targets Ther. 2017 May 11;10:2539-2551. doi: 10.2147/OTT.S102569. eCollection 2017.
    • Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer.
    • Rubio Pérez MJ.
    • Case Rep Oncol. 2017 May 9;10(2):433-437. doi: 10.1159/000475707. eCollection 2017 May-Aug.
    • A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    • Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G.
    • Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049.
    • Whence High-Grade Serous Ovarian Cancer.
    • Kohn EC, Ivy SP.
    • Am Soc Clin Oncol Educ Book. 2017 May;(37):443-448. doi: 10.1200/EDBK_174718.
    • Cancers de l’ovaire BRCA muté : consultation d’oncogénétique et prescription des inhibiteurs de PARP. [BRCA-mutated Ovarian Carcinomas: Genetic Counseling and PARP Inhibitors Prescription.]
    • Gladieff L, Lyonnet DS, Lortholary A, Leary A, Genestie C, Ray-Coquard I.
    • Bull Cancer. 2017 May;104 Suppl 1:S16-S23. doi: 10.1016/S0007-4551(17)30158-3.
    • Review, [Article in French]
    • Traitement des rechutes tardives du cancer de l’ovaire. [Treatment for Platinum-Sensitive Relapses of Ovarian Cancer.]
    • Floquet A, Berton-Rigaud D, Ferron G, Freyer G, Hardy-Bessard AC, You B.
    • Bull Cancer. 2017 May;104 Suppl 1:S24-S31. doi: 10.1016/S0007-4551(17)30159-5.
    • Review, [Article in French]
    • Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
    • George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA.
    • Eur J Cancer. 2017 May;76:52-59. doi: 10.1016/j.ejca.2017.01.020. Epub 2017 Mar 6.
    • Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
    • Coghlan E, Meniawy TM, Munro A, Bulsara M, Stewart CJ, Tan A, Koay ME, MaGee D, Codde J, Tan J, Salfinger SG, Mohan GR, Leung Y, Nichols CB, Cohen PA.
    • Int J Gynecol Cancer. 2017 May;27(4):708-713. doi: 10.1097/IGC.0000000000000945.
    • Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
    • George A, Kaye S, Banerjee S.
    • Nat Rev Clin Oncol. 2017 May;14(5):284-296. doi: 10.1038/nrclinonc.2016.191. Epub 2016 Dec 13.
    • Review
    • Myriad to Use BRACAnalysis CDx as Companion Diagnostic for Clovis' Ovarian Cancer Treatment.
    • [No author given]
    • Clinical Omics. 2017 Apr 27.
    • Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
    • Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL.
    • J Clin Oncol. 2017 Apr 20;35(12):1274-1280. doi: 10.1200/JCO.2016.70.4627. Epub 2017 Feb 13.
    • Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib.
    • McCormick A, Donoghue P, Dixon M, O'Sullivan R, O'Donnell RL, Murray J, Kaufmann A, Curtin NJ, Edmondson RJ.
    • Clin Cancer Res. 2017 Apr 15;23(8):2050-2060. doi: 10.1158/1078-0432.CCR-16-0564. Epub 2016 Oct 4.
    • Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance.
    • Anantha RW, Simhadri S, Foo TK, Miao S, Liu J, Shen Z, Ganesan S, Xia B.
    • Elife. 2017 Apr 11;6. pii: e21350. doi: 10.7554/eLife.21350.
    • Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    • Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, Oza AM.
    • J Clin Oncol. 2017 Apr 10;35(11):1240-1249. doi: 10.1200/JCO.2016.71.3677. Epub 2017 Feb 21.
    • PARP Inhibitors for Cancer Therapy.
    • Lin KY, Kraus WL.
    • Cell. 2017 Apr 6;169(2):183. doi: 10.1016/j.cell.2017.03.034.
    • Review
    • Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.
    • El Bairi K, Kandhro AH, Gouri A, Mahfoud W, Louanjli N, Saadani B, Afqir S, Amrani M.
    • Cell Oncol (Dordr). 2017 Apr;40(2):105-118. doi: 10.1007/s13402-016-0309-1. Epub 2016 Dec 15.
    • Review
    • Rucaparib: First Global Approval.
    • Syed YY.
    • Drugs. 2017 Apr;77(5):585-592. doi: 10.1007/s40265-017-0716-2.
    • Review
    • Niraparib for the treatment of ovarian cancer.
    • Kanjanapan Y, Lheureux S, Oza AM.
    • Expert Opin Pharmacother. 2017 Apr;18(6):631-640. doi: 10.1080/14656566.2017.1297423. Epub 2017 Apr 7.
    • Review
    • Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.
    • Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH.
    • J Immunother. 2017 Apr;40(3):104-107. doi: 10.1097/CJI.0000000000000160.
    • Case report
    • PARP inhibitors in ovarian cancer: evidence, experience and clinical potential.
    • Evans T, Matulonis U.
    • Ther Adv Med Oncol. 2017 Apr;9(4):253-267. doi: 10.1177/1758834016687254. Epub 2017 Feb 3.
    • Niraparib for the treatment of ovarian cancer.
    • Kanjanapan Y, Lheureux S, Oza AM.
    • Expert Opin Pharmacother. 2017 Mar 16. doi: 10.1080/14656566.2017.1297423. [Epub ahead of print]
    • Review
    • Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
    • Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou V, Murphy RF, Widemann BC, Figg WD, Kohn EC.
    • Clin Cancer Res. 2017 Mar 15;23(6):1397-1406. doi: 10.1158/1078-0432.CCR-16-1546. Epub 2016 Sep 23.
    • Olaparib Maintenance Therapy Boosts PFS in Ovarian Cancer.
    • Nelson R.
    • Medscape. 2017 Mar 14.
    • Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm.
    • McGrail DJ, Lin CC, Garnett J, Liu Q, Mo W, Dai H, Lu Y, Yu Q, Ju Z, Yin J, Vellano CP, Hennessy B, Mills GB, Lin SY.
    • NPJ Syst Biol Appl. 2017 Mar 6;3:8. doi: 10.1038/s41540-017-0011-6. eCollection 2017.
    • Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer.
    • Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E.
    • Ann Oncol. 2017 Mar 1;28(3):512-518. doi: 10.1093/annonc/mdw672.
    • Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences.
    • Kurian AW, Friese CR, Bondarenko I, Jagsi R, Li Y, Hamilton AS, Ward KC, Katz SJ.
    • JAMA Oncol. 2017 Mar 1;3(3):391-397. doi: 10.1001/jamaoncol.2016.5652.
    • Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
    • Mittapalli RK, Nuthalapati S, Shepherd SP, Xiong H.
    • Cancer Chemother Pharmacol. 2017 Mar;79(3):587-594. doi: 10.1007/s00280-017-3262-4. Epub 2017 Feb 28.
    • A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.
    • Reiss KA, Herman JM, Armstrong D, Zahurak M, Fyles A, Brade A, Milosevic M, Dawson LA, Scardina A, Fischer P, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Stayner LA, Siu LL, Azad NS.
    • Gynecol Oncol. 2017 Mar;144(3):486-490. doi: 10.1016/j.ygyno.2017.01.016. Epub 2017 Jan 18.
    • HDAC10 as a potential therapeutic target in ovarian cancer.
    • Islam MM, Banerjee T, Packard CZ, Kotian S, Selvendiran K, Cohn DE, Parvin JD.
    • Gynecol Oncol. 2017 Mar;144(3):613-620. doi: 10.1016/j.ygyno.2017.01.009. Epub 2017 Jan 7.
    • [BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy].
    • Löser H, Heydt C, Büttner R, Markiefka B.
    • Pathologe. 2017 Mar;38(2):117-126. doi: 10.1007/s00292-017-0274-0.
    • Review, [Article in German]
    • Pharmaceutical Approval Update.
    • Choy M.
    • P T. 2017 Mar;42(3):165-166.
    • Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.
    • Frey MK, Pothuri B.
    • Gynecol Oncol Res Pract. 2017 Feb 22;4:4. doi: 10.1186/s40661-017-0039-8. eCollection 2017.
    • Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.
    • De Jaeghere E, Vandecasteele K, Claes K, Makar A, Tummers P, Cocquyt V, Denys H.
    • Acta Clin Belg. 2017 Feb;72(1):6-11. doi: 10.1080/17843286.2016.1188455. Epub 2016 May 31.
    • Review
    • PARP-1 Expression Quantified by [18F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy.
    • Sander Effron S, Makvandi M, Lin L, Xu K, Li S, Lee H, Hou C, Pryma DA, Koch C, Mach RH.
    • Cancer Biother Radiopharm. 2017 Feb;32(1):9-15. doi: 10.1089/cbr.2016.2133. Epub 2017 Jan 24.
    • Rucaparib Approved for Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2017 Feb;7(2):120-121. doi: 10.1158/2159-8290.CD-NB2016-164. Epub 2017 Jan 5.
    • News
    • Integrating genomic information and signaling dynamics for efficient cancer therapy.
    • Stewart-Ornstein J, Lahav G.
    • Curr Opin Syst Biol. 2017 Feb;1:38-43. doi: 10.1016/j.coisb.2016.12.013. Epub 2016 Dec 19.
    • Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
    • Rzepecka IK, Szafron LM, Stys A, Felisiak-Golabek A, Podgorska A, Timorek A, Sobiczewski P, Pienkowska-Grela B, El-Bahrawy M, Kupryjanczyk J.
    • Gynecol Oncol. 2017 Feb;144(2):369-376. doi: 10.1016/j.ygyno.2016.11.028. Epub 2016 Dec 7.
    • Novel BRCA1 and BRCA2 Tumour Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
    • Weren RD, Mensenkamp AR, Simons M, Eijkelenboom A, Sie AS, Ouchene H, van Asseldonk M, Gomez-Garcia EB, Blok MJ, de Hullu JA, Nelen MR, Hoischen A, Bulten J, Tops BB, Hoogerbrugge N, Ligtenberg EM.
    • Hum Mutat. 2017 Feb;38(2):226-235. doi: 10.1002/humu.23137. Epub 2016 Nov 9.
    • [Can new molecular profiles in epithelial ovarian cancer modify therapeutics?]
    • Lavoué V, Rousselin A, Delplanque S, Pinsard M, Henno S, Foucher F, Levêque J, de la Motte Rouge T.
    • J Gynecol Obstet Hum Reprod. 2017 Feb;46(2):107-112. doi: 10.1016/j.jogoh.2016.09.002. Epub 2017 Jan 30.
    • Review, [Article in French]
    • Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
    • Wilkerson PM, Dedes KJ, Samartzis EP, Dedes I, Lambros MB, Natrajan R, Gauthier A, Piscuoglio S, Töpfer C, Vukovic V, Daley F, Weigelt B, Reis-Filho JS.
    • Oncotarget. 2017 Jan 24;8(4):6057-6066. doi: 10.18632/oncotarget.14011.
    • The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.
    • Yan S, Frank D, Son J, Hannan KM, Hannan RD, Chan KT, Pearson RB, Sanij E.
    • Int J Mol Sci. 2017 Jan 20;18(1). pii: E210. doi: 10.3390/ijms18010210.
    • Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
    • Brandt S, Samartzis EP, Zimmermann AK, Fink D, Moch H, Noske A, Dedes KJ.
    • BMC Cancer. 2017 Jan 10;17(1):44. doi: 10.1186/s12885-016-3026-2.
    • Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
    • Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, Del Carmen MG, Keating NL.
    • JAMA Oncol. 2017 Jan 1;3(1):76-82. doi: 10.1001/jamaoncol.2016.4411.
    • Genomic LOH May Predict Rucaparib Response in Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2017 Jan;7(1):OF8. doi: 10.1158/2159-8290.CD-RW2016-230. Epub 2016 Dec 9.
    • Research News
    • Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.
    • Lambertini M, Del Mastro L, Viglietti G, Pondé NF, Solinas C, de Azambuja E.
    • Curr Treat Options Oncol. 2017 Jan;18(1):4. doi: 10.1007/s11864-017-0442-8.
    • Review
    • Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
    • Bergamini A, Pisano C, Di Napoli M, Arenare L, Della Pepa C, Tambaro R, Facchini G, Gargiulo P, Rossetti S, Mangili G, Pignata S, Cecere SC.
    • Gynecol Oncol. 2017 Jan;144(1):72-76. doi: 10.1016/j.ygyno.2016.10.023. Epub 2016 Oct 27.
    • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    • Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA.
    • Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.

    Comment:

    Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?

    • Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    • Tappenden P, Harnan S, Ren S, Thokala P, Wong R, Mukuria C, Green C, Pledge S, Tidy J.
    • Pharmacoeconomics. 2017 Jan;35(1):97-109. doi: 10.1007/s40273-016-0440-x.
    • Olaparib (LYNPARZAO) Ovarian cancer: spare patients who are in remission.
    • [No authors listed]
    • Prescrire Int. 2017 Jan;26(178):9-12.
    • Fork Protection and Therapy Resistance in Hereditary Breast Cancer.
    • Cantor SB, Calvo JA.
    • Cold Spring Harb Symp Quant Biol. 2017;82:339-348. doi: 10.1101/sqb.2017.82.034413. Epub 2018 Feb 22.
    • Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor Olaparib by a dominant negative effect.
    • Vaclová T, Woods NT, Megías D, Gomez-Lopez S, Setién F, García Bueno JM, Macías JA, Barroso A, Urioste M, Esteller M, Monteiro AN, Benítez J, Osorio A.
    • Hum Mol Genet. 2016 Dec 15;25(24):5287-5299. doi: 10.1093/hmg/ddw343.
    • Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.
    • Friedlander M, Banerjee S, Mileshkin L, Scott C, Shannon C, Goh J.
    • Asia Pac J Clin Oncol. 2016 Dec;12(4):323-331. doi: 10.1111/ajco.12636.
    • Niraparib Slows Ovarian Cancer Progression.
    • [No authors listed]
    • Cancer Discov. 2016 Dec;6(12):OF2. Epub 2016 Nov 3.
    • News
    • Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
    • Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F, Ray-Coquard I, Stoppa-Lyonnet D, Gonzalez-Martin A, Sehouli J, Colombo N.
    • Eur J Cancer. 2016 Dec;69:127-134. doi: 10.1016/j.ejca.2016.10.006. Epub 2016 Nov 4.
    • Review
    • Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
    • Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators.
    • N Engl J Med. 2016 Dec;375(22):2154-2164. Epub 2016 Oct 7.

    Editorial, Comment:

    PARP Inhibitors in Ovarian Cancer Treatment.

    Letter, Comment:

    Niraparib in Recurrent Ovarian Cancer.

    Press: New PARP Drug 'Could Benefit Most Ovarian Cancer Patients'. (Medscape)

    • PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting.
    • Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A.
    • Prz Menopauzalny. 2016 Dec;15(4):215-219. doi: 10.5114/pm.2016.65667. Epub 2017 Feb 8.
    • Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?
    • Egloff H, Jatoi A.
    • Cancer Invest. 2016 Nov 25;34(10):531-535. Epub 2016 Oct 28.
    • Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
    • Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Bennett B, Parry D, Spencer S, Mann H, Matulonis U.
    • Br J Cancer. 2016 Nov 22;115(11):1313-1320. doi: 10.1038/bjc.2016.348. Epub 2016 Nov 8.
    • PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
    • Konecny GE, Kristeleit RS.
    • Br J Cancer. 2016 Nov 8;115(10):1157-1173. doi: 10.1038/bjc.2016.311. Epub 2016 Oct 13.
    • Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    • Monk BJ, Lorusso D, Italiano A, Kaye SB, Aracil M, Tanović A, D'Incalci M.
    • Cancer Treat Rev. 2016 Nov;50:175-182. doi: 10.1016/j.ctrv.2016.09.009. Epub 2016 Sep 15.
    • Review
    • [Perspectives of Individualized Treatment by Genome-Wide Analyses in Ovarian Cancer].
    • Matsumura N, Yamaguchi K, Murakami R, Mandai M, Konishi I.
    • Gan To Kagaku Ryoho. 2016 Nov;43(11):1316-1320.
    • [Article in Japanese]
    • In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
    • AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P.
    • Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8.
    • Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    • Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U.
    • Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.
    • Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease.
    • Bangham M, Goldstein R, Walton H, Ledermann JA.
    • Gynecol Oncol Rep. 2016 Oct 19;18:22-24. eCollection 2016.
    • The current status of PARP inhibitors in ovarian cancer.
    • McLachlan J, George A, Banerjee S.
    • Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24.
    • Review
    • The race to create a new class of ovarian cancer drugs heats up.
    • Meghana Keshavan
    • STAT. 2016 Oct 8.
    • Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
    • Sabatier R, Lavit E, Moretta J, Lambaudie E, Noguchi T, Eisinger F, Cherau E, Provansal M, Livon D, Rabayrol L, Popovici C, Charaffe-Jauffret E, Sobol H, Viens P.
    • Fam Cancer. 2016 Oct;15(4):497-506. doi: 10.1007/s10689-016-9873-9.
    • Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
    • Wilson AJ, Sarfo-Kantanka K, Barrack T, Steck A, Saskowski J, Crispens MA, Khabele D.
    • Gynecol Oncol. 2016 Oct;143(1):143-51. doi: 10.1016/j.ygyno.2016.07.088. Epub 2016 Jul 19.
    • Ovarian cancer treatment in mutation carriers/brcaness.
    • Lorusso D, Perotto S.
    • Minerva Ginecol. 2016 Oct;68(5):566-78. Epub 2016 Jan 19.
    • Review
    • Linking genotoxicity and cytotoxicity with membrane fluidity: A comparative study in ovarian cancer cell lines following exposure to auranofin.
    • Oommen D, Dodd NJ, Yiannakis D, Moyeed R, Jha AN.
    • Mutat Res. 2016 Oct;809:43-49. doi: 10.1016/j.mrgentox.2016.09.003. Epub 2016 Sep 4.
    • Sequence-specific pharmacokinetic and pharmacodynamic phase I/Ib study of olaparib tablets and carboplatin in women's cancer.
    • Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou V, Murphy RF, Widemann BC, Figg WD, Kohn EC.
    • Clin Cancer Res. 2016 Sep 23. pii: clincanres.1546.2016. [Epub ahead of print]
    • Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    • Papa A, Caruso D, Strudel M, Tomao S, Tomao F.
    • J Transl Med. 2016 Sep 15;14:267. doi: 10.1186/s12967-016-1027-1.
    • [BRCA1 and BRCA2 - pathologists starting kit].
    • Škapa P.
    • Cesk Patol. 2016 Fall;52(4):193-196.
    • [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    • Škapa P, Dundr P.
    • Cesk Patol. 2016 Fall;52(4):199-204.
    • [Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
    • Vošmiková H, Ryška A, Sieglová K, Laco J.
    • Cesk Patol. 2016 Fall;52(4):210-214.
    • PTIP Loss Protects BRCA-Deficient Cells from DNA Damage and Cell Death.
    • [No authors listed]
    • Cancer Discov. 2016 Sep;6(9):944. doi: 10.1158/2159-8290.CD-RW2016-142. Epub 2016 Jul 29.
    • Research Watch
    • New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes.
    • Vergote I, Bours V, Blaumeiser B, Baurain JF.
    • Facts Views Vis Obgyn. 2016 Sep;8(3):161-167.
    • Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.
    • Pinto C, Bella MA, Capoluongo E, Carrera P, Clemente C, Colombo N, Cortesi L, De Rosa G, Fenizia F, Genuardi M, Gori S, Guarneri V, Marchetti A, Marchetti P, Normanno N, Pasini B, Pignata S, Radice P, Ricevuto E, Russo A, Tagliaferri P, Tassone P, Truini M, Varesco L.
    • Future Oncol. 2016 Sep;12(18):2071-5. doi: 10.2217/fon-2016-0189. Epub 2016 May 31.
    • Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    • Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P.
    • Gynecol Oncol. 2016 Sep;142(3):548-56. doi: 10.1016/j.ygyno.2016.07.092. Epub 2016 Jul 15.
    • PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials.
    • Crafton SM, Bixel K, Hays JL.
    • Gynecol Oncol. 2016 Sep;142(3):588-96. doi: 10.1016/j.ygyno.2016.05.003. Epub 2016 Jul 25.
    • Review
    • PARP Inhibitors Promising as Maintenance After Ovarian Cancer Remission.
    • Maurie Markman
    • Medscape Oncology. 2016 Aug 23.
    • All women with ovarian cancer should be offered genetic testing – so why aren’t they?
    • Emma Smith
    • Science Blog. Cancer Research UK. 2016 Aug 17.
    • BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
    • Moschetta M, George A, Kaye SB, Banerjee S.
    • Ann Oncol. 2016 Aug;27(8):1449-55. doi: 10.1093/annonc/mdw142. Epub 2016 Mar 31.
    • Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    • Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, Ali-Fehmi R, Buekers T, Munkarah AR, Rattan R.
    • Gynecol Oncol. 2016 Aug;142(2):323-31. doi: 10.1016/j.ygyno.2016.06.005. Epub 2016 Jun 16.
    • Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    • Moore KN, Monk BJ.
    • Oncologist. 2016 Aug;21(8):954-63. doi: 10.1634/theoncologist.2015-0268. Epub 2016 Jun 2.
    • MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    • Whicker ME, Lin ZP, Hanna R, Sartorelli AC, Ratner ES.
    • BMC Cancer. 2016 Jul 27;16(1):550. doi: 10.1186/s12885-016-2598-1.
    • Single-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer Patients.
    • Zimmermann MT, Jiang G, Wang C.
    • AMIA Jt Summits Transl Sci Proc. 2016 Jul 20;2016:94-100. eCollection 2016.
    • Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
    • Munroe M, Kolesar J.
    • Am J Health Syst Pharm. 2016 Jul 15;73(14):1037-41. doi: 10.2146/ajhp150550.
    • Review
    • PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency.
    • Noll A, Illuzzi G, Amé JC, Dantzer F, Schreiber V.
    • Cancer Cell Int. 2016 Jul 1;16:53. doi: 10.1186/s12935-016-0333-2. eCollection 2016.
    • Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target.
    • Goyal G, Fan T, Silberstein PT.
    • Fam Cancer. 2016 Jul;15(3):359-66. doi: 10.1007/s10689-016-9883-7.
    • Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
    • Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Parry D, Grinsted L, Ledermann JA.
    • Cancer. 2016 Jun 15;122(12):1844-52. doi: 10.1002/cncr.29995. Epub 2016 Apr 8.
    • Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    • Moore KN, Monk BJ.
    • Oncologist. 2016 Jun 2. pii: theoncologist.2015-0268. [Epub ahead of print]
    • Review
    • Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
    • Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL.
    • Ann Oncol. 2016 Jun;27(6):1013-9. doi: 10.1093/annonc/mdw133. Epub 2016 Mar 8.
    • Homologous recombination deficiency and ovarian cancer.
    • Ledermann JA, Drew Y, Kristeleit RS.
    • Eur J Cancer. 2016 Jun;60:49-58. doi: 10.1016/j.ejca.2016.03.005. Epub 2016 Apr 9.
    • Review
    • The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
    • Nirsimloo R, Gourley C.
    • Expert Rev Anticancer Ther. 2016 Jun;16(6):597-603. doi: 10.1080/14737140.2016.1182429.
    • Review
    • Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.
    • Jenner ZB, Sood AK, Coleman RL.
    • Future Oncol. 2016 Jun;12(12):1439-56. doi: 10.2217/fon-2016-0002. Epub 2016 Apr 18.
    • Review
    • Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer.
    • Komiyama S, Katabuchi H, Mikami M, Nagase S, Okamoto A, Ito K, Morishige K, Suzuki N, Kaneuchi M, Yaegashi N, Udagawa Y, Yoshikawa H.
    • Int J Clin Oncol. 2016 Jun;21(3):435-46. doi: 10.1007/s10147-016-0985-x. Epub 2016 May 3.
    • Practice Guideline
    • Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer.
    • Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao H, Zhong Z, Sun J.
    • Oncotarget. 2016 May 31;7(22):32433-48. doi: 10.18632/oncotarget.8653.
    • Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
    • Kristeleit RS, Miller RE, Kohn EC.
    • Am Soc Clin Oncol Educ Book. 2016 May;(36):e259-e268. doi: 10.1200/EDBK_159086.
    • PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
    • Gadducci A, Guerrieri ME.
    • Anticancer Res. 2016 May;36(5):2055-64.
    • Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
    • De Picciotto N, Cacheux W, Roth A, Chappuis PO, Labidi-Galy SI.
    • Crit Rev Oncol Hematol. 2016 May;101:50-9. doi: 10.1016/j.critrevonc.2016.02.014. Epub 2016 Feb 27.
    • Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues.
    • Ju LL, Zhao CY, Ye KF, Yang H, Zhang J.
    • Eur Rev Med Pharmacol Sci. 2016 May;20(10):1993-2003.
    • Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    • Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.
    • Expert Opin Investig Drugs. 2016 May;25(5):597-611. doi: 10.1517/13543784.2016.1156857. Epub 2016 Mar 16.
    • Olaparib for the treatment of epithelial ovarian cancer.
    • McLachlan J, Banerjee S.
    • Expert Opin Pharmacother. 2016 May;17(7):995-1003. doi: 10.1517/14656566.2016.1165205. Epub 2016 Apr 4.
    • Review
    • Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
    • Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA.
    • Gynecol Oncol. 2016 May;141(2):260-3. doi: 10.1016/j.ygyno.2016.03.010. Epub 2016 Mar 11.
    • Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    • Parkes EE, Kennedy RD.
    • Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28.
    • Review
    • Profile of olaparib in the treatment of advanced ovarian cancer.
    • Chase DM, Patel S, Shields K.
    • Int J Womens Health. 2016 Apr 18;8:125-9. doi: 10.2147/IJWH.S55906. eCollection 2016.
    • Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.
    • Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD.
    • Oncotarget. 2016 Apr 12;7(15):20825-39. doi: 10.18632/oncotarget.7883.
    • Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
    • Kaye SB.
    • Ann Oncol. 2016 Apr;27 Suppl 1:i1-i3. doi: 10.1093/annonc/mdw082.
    • PARP inhibitors in ovarian cancer.
    • Ledermann JA.
    • Ann Oncol. 2016 Apr;27 Suppl 1:i40-i44. doi: 10.1093/annonc/mdw094.
    • Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
    • Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, Yang D.
    • Gynecol Oncol. 2016 Apr;141(1):57-64. doi: 10.1016/j.ygyno.2016.01.004.
    • Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.
    • Bai H, Cao D, Yang J, Li M, Zhang Z, Shen K.
    • J Cell Mol Med. 2016 Apr;20(4):581-93. doi: 10.1111/jcmm.12771. Epub 2016 Jan 22.
    • Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    • Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R.
    • Br J Cancer. 2016 Mar 29;114(7):723-30. doi: 10.1038/bjc.2016.41. Epub 2016 Mar 22.
    • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    • Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, Matulonis UA, Konstantinopoulos PA.
    • Oncotarget. 2016 Mar 22;7(12):13587-98. doi: 10.18632/oncotarget.7277.
    • Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer.
    • Li D, Wu QJ, Bi FF, Chen SL, Zhou YM, Zhao Y, Yang Q.
    • Am J Transl Res. 2016 Mar 15;8(3):1601-8. eCollection 2016.
    • Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
    • Wang D, Wang M, Jiang N, Zhang Y, Bian X, Wang X, Roberts TM, Zhao JJ, Liu P, Cheng H.
    • Oncotarget. 2016 Mar 15;7(11):13153-66. doi: 10.18632/oncotarget.7549.
    • Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments.
    • Lokadasan R, James FV, Narayanan G, Prabhakaran PK.
    • Ecancermedicalscience. 2016 Mar 8;10:626. doi: 10.3332/ecancer.2016.626. eCollection 2016.
    • Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
    • Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, Sabbatini R, Artioli G, Gamucci T, Di Napoli M, Capoluongo E, Ludovini V, Raspagliesi F, Ferrandina G.
    • Ann Oncol. 2016 Mar;27(3):487-93. doi: 10.1093/annonc/mdv608. Epub 2015 Dec 17.
    • Veliparib for the treatment of ovarian cancer.
    • Bogliolo S, Cassani C, Dominoni M, Musacchi V, Venturini PL, Spinillo A, Ferrero S, Gardella B.
    • Expert Opin Investig Drugs. 2016 Mar;25(3):367-74. doi: 10.1517/13543784.2016.1146677. Epub 2016 Feb 16.
    • Review
    • NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer.
    • Tucker H, Charles Z, Robertson J, Adam J.
    • Lancet Oncol. 2016 Mar;17(3):277-8. doi: 10.1016/S1470-2045(16)00062-0. Epub 2016 Jan 27.
    • News
    • New treatment option for ovarian cancer: PARP inhibitors.
    • Meehan RS, Chen AP.
    • Gynecol Oncol Res Pract. 2016 Feb 26;3:3. doi: 10.1186/s40661-016-0024-7. eCollection 2016.
    • Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptormediated apoptosis.
    • De Toni EN, Ziesch A, Rizzani A, Török HP, Hocke S, Lü S, Wang SC, Hucl T, Göke B, Bruns C, Gallmeier E.
    • Oncotarget. 2016 Feb 23;7(8):9477-90. doi: 10.18632/oncotarget.7053.
    • Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
    • Bao Z, Cao C, Geng X, Tian B, Wu Y, Zhang C, Chen Z, Li W, Shen H, Ying S.
    • Oncotarget. 2016 Feb 16;7(7):7629-39. doi: 10.18632/oncotarget.5367.
    • Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.
    • Zimmer J, Tacconi EM, Folio C, Badie S, Porru M, Klare K, Tumiati M, Markkanen E, Halder S, Ryan A, Jackson SP, Ramadan K, Kuznetsov SG, Biroccio A, Sale JE, Tarsounas M.
    • Mol Cell. 2016 Feb 4;61(3):449-60. doi: 10.1016/j.molcel.2015.12.004. Epub 2015 Dec 31.
    • BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranofin.
    • Oommen D, Yiannakis D, Jha AN.
    • Mutat Res. 2016 Feb-Mar;784-785:8-15. doi: 10.1016/j.mrfmmm.2015.11.002. Epub 2015 Nov 28.
    • Leveraging DNA repair deficiency in gynecologic oncology.
    • Walsh CS, Hodeib M.
    • Curr Opin Obstet Gynecol. 2016 Feb;28(1):24-31. doi: 10.1097/GCO.0000000000000236.
    • Review
    • PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives.
    • Sehouli J, Braicu EI, Chekerov R.
    • Geburtshilfe Frauenheilkd. 2016 Feb;76(2):164-169.
    • Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
    • Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Loman N, Robertson JD, Mann H, Kaufman B.
    • Gynecol Oncol. 2016 Feb;140(2):199-203. doi: 10.1016/j.ygyno.2015.12.020. Epub 2015 Dec 23.
    • A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
    • Bell-McGuinn KM, Konner JA, Tew WP, Hensley ML, Iasonos A, Charpentier E, Mironov S, Sabbatini P, Aghajanian C.
    • Int J Gynecol Cancer. 2016 Feb;26(2):255-60. doi: 10.1097/IGC.0000000000000591.
    • Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
    • Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, Weinstock DM, Dao F, Shih KK, Matulonis U, Levine DA, Konstantinopoulos PA, Chowdhury D.
    • Cell Rep. 2016 Jan 26;14(3):429-439. doi: 10.1016/j.celrep.2015.12.046. Epub 2016 Jan 7.
    • Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
    • Nomura H, Kataoka F, Aoki D, Jinno H, Kitagawa Y, Sato Y, Womack C, Wombwell H, Hodgson D, O'Connor M, Harbron C, Yin X.
    • Cancer Biomark. 2016 Jan 18;16(1):145-52. doi: 10.3233/CBM-150550.
    • BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    • Mafficini A, Simbolo M, Parisi A, Rusev B, Luchini C, Cataldo I, Piazzola E, Sperandio N, Turri G, Franchi M, Tortora G, Bovo C, Lawlor RT, Scarpa A.
    • Oncotarget. 2016 Jan 12;7(2):1076-83. doi: 10.18632/oncotarget.6834.
    • Olaparib.
    • Goulooze SC, Cohen AF, Rissmann R.
    • Br J Clin Pharmacol. 2016 Jan;81(1):171-3. doi: 10.1111/bcp.12761. Epub 2015 Oct 24.
    • Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    • Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S.
    • Drug Resist Updat. 2016 Jan;24:55-69. doi: 10.1016/j.drup.2015.11.005. Epub 2015 Nov 26.
    • Olaparib for the treatment of ovarian cancer.
    • Bornstein E, Jimeno A.
    • Drugs Today (Barc). 2016 Jan;52(1):17-28. doi: 10.1358/dot.2016.52.1.2440714.
    • Review
    • Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    • Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote I.
    • Eur J Cancer. 2016 Jan;53:51-64. doi: 10.1016/j.ejca.2015.11.001. Epub 2015 Dec 13.
    • Genomic testing and precision medicine - What does this mean for gynecologic oncology?
    • Liu J, Konstantinopoulos PA, Matulonis UA.
    • Gynecol Oncol. 2016 Jan;140(1):3-5. doi: 10.1016/j.ygyno.2015.12.001. Epub 2015 Dec 4.
    • Treatment related toxicity in BRCA1-associated epithelial ovarian cancer - is DNA repairing impairment associated with more adverse events?
    • Badora-Rybicka A, Budryk M, Nowara E, Starzyczny-Słota D.
    • Contemp Oncol (Pozn). 2016;20(5):381-384. doi: 10.5114/wo.2016.64597. Epub 2016 Dec 20.
    • Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer.
    • LaFargue CJ, Tewari KS.
    • Recent Pat Biotechnol. 2016;9(2):86-101.
    • Review
    • 2016 Genetics Toolkit
    • Society of Gynecologic Oncology
    • Society of Gynecologic Oncology. 2016.

    News: New Toolkit Can Help Debunk Myths About Genetic Testing for Gynecologic Cancer. (Cure)

    • [Specific features of drug sensitivity of hereditary cancers].
    • Imyanitov EN.
    • Vopr Onkol. 2016;62(2):221-6.
    • Review, [Article in Russian]
    • High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.
    • Gorodnova TV, Sokolenko AP, Ivantsov AO, Iyevleva AG, Suspitsin EN, Aleksakhina SN, Yanus GA, Togo AV, Maximov SY, Imyanitov EN.
    • Cancer Lett. 2015 Dec 28;369(2):363-7. doi: 10.1016/j.canlet.2015.08.028. Epub 2015 Sep 2.
    • PARP inhibitors in ovarian cancer.
    • Cibula D, Balmaña J.
    • Br J Cancer. 2015 Dec 15;113(S1):S1-S2. doi: 10.1038/bjc.2015.392.
    • Introductory article
    • The development of PARP inhibitors in ovarian cancer: from bench to bedside.
    • Drew Y.
    • Br J Cancer. 2015 Dec 15;113(S1):S3-S9. doi: 10.1038/bjc.2015.394.
    • Review
    • PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions.
    • Ledermann JA, El-Khouly F.
    • Br J Cancer. 2015 Dec 15;113(S1):S10-S16. doi: 10.1038/bjc.2015.395.
    • Review
    • UK BRCA mutation testing in patients with ovarian cancer.
    • George A.
    • Br J Cancer. 2015 Dec 15;113(S1):S17-S21. doi: 10.1038/bjc.2015.396.
    • Review
    • Individualiserad behandling vid ovarialcancer kan bli möjlig.
    • Kjölhede P, Dahm-Kähler P, Tholander B, Åvall Lundqvist E.
    • Lakartidningen. 2015 Dec 8;112. pii: DLUF.
    • Targeting tumor suppressor genes for cancer therapy.
    • Liu Y, Hu X, Han C, Wang L, Zhang X, He X, Lu X.
    • Bioessays. 2015 Dec;37(12):1277-86. doi: 10.1002/bies.201500093. Epub 2015 Oct 7.
    • Review
    • Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer.
    • Mahdi H, Gockley A, Esselen K, Marquard J, Nutter B, Yang B, Hinchcliff E, Horowitz N, Rose PG.
    • Gynecol Oncol. 2015 Dec;139(3):407-412. doi: 10.1016/j.ygyno.2015.07.101. Epub 2015 Jul 23.
    • Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
    • Patrono MG, Iniesta MD, Malpica A, Lu KH, Fernandez RO, Salvo G, Ramirez PT.
    • Gynecol Oncol. 2015 Dec;139(3):568-572. doi: 10.1016/j.ygyno.2015.09.018. Epub 2015 Sep 25.
    • Review
    • Outcomes of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced stage Müllerian cancer.
    • Emily Hinchcliff, Haider Mahdi, Allison Gockley, Katharine Esselen, Jessica Marquard, Benjamin Nutter, Bin Yang, Peter G. Rose, Neil Horowitz.
    • Gynecologic Oncology. 2015 Dec;139(3):589. 2015 NEAGO ABSTRACTS. doi: 10.1016/j.ygyno.2015.09.036.
    • Conference abstract
    • Clinical Practice Guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families.
    • Singer CF, Tea MK, Pristauz G, Hubalek M, Rappaport C, Riedl CC, Helbich TH.
    • Wien Klin Wochenschr. 2015 Dec;127(23-24):981-6. doi: 10.1007/s00508-015-0880-x. Epub 2015 Nov 2.
    • Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers.
    • Chandramouly G, McDevitt S, Sullivan K, Kent T, Luz A, Glickman JF, Andrake M, Skorski T, Pomerantz RT.
    • Chem Biol. 2015 Nov 19;22(11):1491-504. doi: 10.1016/j.chembiol.2015.10.003. Epub 2015 Nov 5.
    • Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
    • Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD.
    • Cancer Discov. 2015 Nov;5(11):1137-54. doi: 10.1158/2159-8290.CD-15-0714. Epub 2015 Oct 13.
    • CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
    • Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams SF.
    • Cancer Immunol Res. 2015 Nov;3(11):1257-68. doi: 10.1158/2326-6066.CIR-15-0044. Epub 2015 Jul 2.
    • Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.
    • OʼSullivan Coyne G, Chen A, Kummar S.
    • Curr Opin Oncol. 2015 Nov;27(6):475-81. doi: 10.1097/CCO.0000000000000238.
    • Review
    • PARP inhibition: A promising therapeutic target in ovarian cancer.
    • Musella A, Marchetti C, Gasparri ML, Salerno L, Casorelli A, Domenici L, Imperiale L, Ruscito I, Abdul Halim T, Palaia I, Di Donato V, Pecorini F, Monti M, Muzii L, Panici PB.
    • Cell Mol Biol (Noisy-le-grand). 2015 Oct 30;61(6):44-61.
    • Review
    • Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge.
    • Symeonides S, Gourley C.
    • Front Oncol. 2015 Oct 21;5:229. doi: 10.3389/fonc.2015.00229. eCollection 2015.
    • Successes and Challenges of PARP Inhibitors in Cancer Therapy.
    • Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P, Pazdur R.
    • Front Oncol. 2015 Oct 14;5:222. doi: 10.3389/fonc.2015.00222. eCollection 2015.
    • FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
    • Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, Chiu HJ, Ricks TK, Palmby T, Russell AM, Ladouceur G, Pfuma E, Li H, Zhao L, Liu Q, Venugopal R, Ibrahim A, Pazdur R.
    • Clin Cancer Res. 2015 Oct 1;21(19):4257-61. doi: 10.1158/1078-0432.CCR-15-0887. Epub 2015 Jul 17.
    • BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
    • Kan C, Zhang J.
    • Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):281-93. doi: 10.1016/j.ijrobp.2015.05.037.
    • Review
    • [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    • Schreiber V, Illuzzi G, Héberlé E, Dantzer F.
    • Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15.
    • Review, [Article in French]
    • Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
    • Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR.
    • Cancer Chemother Pharmacol. 2015 Oct;76(4):723-9. doi: 10.1007/s00280-015-2836-2. Epub 2015 Aug 5.
    • PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis.
    • Smith HJ, Walters Haygood CL, Arend RC, Leath CA 3rd, Straughn JM Jr.
    • Gynecol Oncol. 2015 Oct;139(1):59-62. doi: 10.1016/j.ygyno.2015.08.013. Epub 2015 Aug 22.
    • Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    • Wiegmans AP, Yap PY, Ward A, Lim YC, Khanna KK.
    • Mol Cancer Ther. 2015 Oct;14(10):2321-31. doi: 10.1158/1535-7163.MCT-15-0374. Epub 2015 Aug 20.
    • Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors.
    • Marques M, Beauchamp MC, Fleury H, Laskov I, Qiang S, Pelmus M, Provencher D, Mes-Masson AM, Gotlieb WH, Witcher M.
    • BMC Med. 2015 Sep 9;13(1):217. doi: 10.1186/s12916-015-0454-9.
    • Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
    • Tewari KS, Eskander RN, Monk BJ.
    • Clin Cancer Res. 2015 Sep 1;21(17):3829-35. doi: 10.1158/1078-0432.CCR-15-0088. Epub 2015 Jul 13.
    • Review
    • A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    • Dietel M, Jöhrens K, Laffert MV, Hummel M, Bläker H, Pfitzner BM, Lehmann A, Denkert C, Darb-Esfahani S, Lenze D, Heppner FL, Koch A, Sers C, Klauschen F, Anagnostopoulos I.
    • Cancer Gene Ther. 2015 Sep;22(9):417-30. doi: 10.1038/cgt.2015.39. Epub 2015 Sep 11.
    • BRACAnalysis CDx as a companion diagnostic tool for Lynparza.
    • Gunderson CC, Moore KN.
    • Expert Rev Mol Diagn. 2015 Sep;15(9):1111-6. doi: 10.1586/14737159.2015.1078238. Epub 2015 Aug 13.
    • Review
    • To BRCA or Not to PALB.
    • McNamara MG, Lamarca A, Hubner RA, Valle JW.
    • J Clin Oncol. 2015 Aug 10;33(23):2581-2. doi: 10.1200/JCO.2014.60.0585. Epub 2015 Jun 29.

    Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    • Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?
    • Copur MS, Gauchan D, Brussow K, Clark D, Ramaekers R.
    • J Clin Oncol. 2015 Aug 10;33(23):2582. doi: 10.1200/JCO.2015.61.0576. Epub 2015 Jun 29.

    Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    • The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer.
    • Huang J, Wang L, Cong Z, Amoozgar Z, Kiner E, Xing D, Orsulic S, Matulonis U, Goldberg MS.
    • Biochem Biophys Res Commun. 2015 Aug 7;463(4):551-6. doi: 10.1016/j.bbrc.2015.05.083. Epub 2015 Jun 3.
    • Olaparib in the management of ovarian cancer.
    • Bixel K, Hays JL.
    • Pharmgenomics Pers Med. 2015 Aug 7;8:127-35. doi: 10.2147/PGPM.S62809. eCollection 2015.
    • Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.
    • Busschots S, O'Toole S, O'Leary JJ, Stordal B.
    • Exp Cell Res. 2015 Aug 1;336(1):1-14. doi: 10.1016/j.yexcr.2014.12.001. Epub 2014 Dec 12.
    • Safety evaluation of olaparib for treating ovarian cancer.
    • Lheureux S, Bowering V, Karakasis K, Oza AM.
    • Expert Opin Drug Saf. 2015 Aug;14(8):1305-16. doi: 10.1517/14740338.2015.1045875. Epub 2015 Jun 8.
    • Review
    • Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
    • van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MW, Harms E, Rehorst H, Sonke GS, Schellens JH.
    • Br J Cancer. 2015 Jul 28;113(3):396-402. doi: 10.1038/bjc.2015.256. Epub 2015 Jul 16.
    • Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    • Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W.
    • JAMA Oncol. 2015 Jul 1;1(4):486-494. doi: 10.1001/jamaoncol.2015.1432.

    Comment

    Gynaecological cancer: ADAMTS mutations predict sensitivity to chemotherapy in ovarian cancer.

    • Challenges in economic modeling of anticancer therapies: an example of modeling the survival benefit of olaparib maintenance therapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer.
    • Hettle R, Posnett J, Borrill J.
    • J Med Econ. [2015 Jul;]18(7):516-24. doi: 10.3111/13696998.2015.1024682. Epub 2015 Apr 7.
    • Genomic Scarring Predicts Rucaparib Activity in Ovarian Cancer.
    • [No author given]
    • ASCO Daily News. 2015 ASCO Annual Meeting. 2015 Jun 1.
    • FDA Approval — How Does it Relate to Germline Genetic Testing?
    • Laura Panos, Sara Gilvary
    • Coding Corner, Perspectives in Genetic Counseling, Volume 37, Number 2, p. 19. 2015 Qtr 2.
    • [Olaparib in ovarian cancer with BRCA mutation].
    • Pujade-Lauraine É, Combe P.
    • Bull Cancer. 2015 Jun;102(6 Suppl 1):S82-4. doi: 10.1016/S0007-4551(15)31221-2.
    • Review, [Article in French]
    • A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
    • Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM.
    • Gynecol Oncol. 2015 Jun;137(3):386-91. doi: 10.1016/j.ygyno.2015.03.042. Epub 2015 Mar 24.
    • The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy.
    • Li M, Yu X.
    • Oncogene. 2015 Jun;34(26):3349-56. doi: 10.1038/onc.2014.295. Epub 2014 Sep 15.
    • Whole-genome characterization of chemoresistant ovarian cancer.
    • Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.
    • Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410.
    • Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    • Wiggans AJ, Cass GK, Bryant A, Lawrie TA, Morrison J.
    • Cochrane Database Syst Rev. 2015 May 20;5:CD007929. doi: 10.1002/14651858.CD007929.pub3.
    • Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
    • Zhu Q, Han SX, Zhou CY, Cai MJ, Dai LP, Zhang JY.
    • Oncotarget. 2015 May 10;6(13):11575-84.
    • Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study†.
    • Monk BJ, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita AS, Nieto A, Park YC, Cheng PS, Li W, Favis R, Ricci D, Poveda A.
    • Ann Oncol. 2015 May;26(5):914-20. doi: 10.1093/annonc/mdv071. Epub 2015 Feb 26.
    • Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
    • Walsh CS.
    • Gynecol Oncol. 2015 May;137(2):343-350. doi: 10.1016/j.ygyno.2015.02.017. Epub 2015 Feb 25.
    • Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
    • Jones P, Wilcoxen K, Rowley M, Toniatti C.
    • J Med Chem. 2015 Apr 23;58(8):3302-14. doi: 10.1021/jm5018237. Epub 2015 Mar 11.
    • Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
    • Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH.
    • Clin Cancer Res. 2015 Apr 1;21(7):1574-82. doi: 10.1158/1078-0432.CCR-14-2565. Epub 2015 Jan 14.
    • Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.
    • Frampton JE.
    • BioDrugs. 2015 Apr;29(2):143-50. doi: 10.1007/s40259-015-0125-6.
    • Review
    • Genetic Testing and Ovarian Cancer.
    • Leigha Ann Senter-Jamieson.
    • NSGC Blog, 2015 Mar 23.
    • Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    • Gunderson CC, Moore KN.
    • Future Oncol. 2015 Mar;11(5):747-57. doi: 10.2217/fon.14.313.
    • Review
    • An update on PARP inhibitors for the treatment of cancer.
    • Benafif S, Hall M.
    • Onco Targets Ther. 2015 Feb 26;8:519-28. doi: 10.2147/OTT.S30793. eCollection 2015.
    • Has the BRCA Monopoly Been Reborn?
    • Ellen T. Matloff.
    • My Gene Counsel. 2015 Feb 24.
    • Regulatory Uncertainty Causing Retesting Confusion for Patients Considering New Ovarian Cancer Rx
    • Turna Ray
    • GenomeWeb, 2015 Feb 16
    • A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance.
    • Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA.
    • Cancer Res. 2015 Feb 15;75(4):628-34. doi: 10.1158/0008-5472.CAN-14-2593. Epub 2015 Jan 29.
    • The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.
    • Gu Y, Zhang M, Peng F, Fang L, Zhang Y, Liang H, Zhou W, Ao L, Guo Z.
    • Oncotarget. 2015 Feb 10;6(4):2397-406.
    • Myriad Discusses Outlook for its Burgeoning CDx Business Following Lynparza Approval
    • Turna Ray
    • GenomeWeb, 2015 Feb 4.
    • News
    • DNA repair mutations and outcomes in ovarian cancer--letter.
    • Soslow RA.
    • Clin Cancer Res. 2015 Feb 1;21(3):658. doi: 10.1158/1078-0432.CCR-14-2436.

    Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

    Comment / Letter

    DNA repair mutations and outcomes in ovarian cancer--response.

    • Familial breast cancer - targeted therapy in secondary and tertiary prevention.
    • Kast K, Rhiem K.
    • Breast Care (Basel). 2015 Feb;10(1):27-31. doi: 10.1159/000380756.
    • Olaparib: first global approval.
    • Deeks ED.
    • Drugs. 2015 Feb;75(2):231-40. doi: 10.1007/s40265-015-0345-6.
    • Review
    • Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?
    • Jacot W, Theillet C, Guiu S, Lamy PJ.
    • Future Oncol. 2015 Feb;11(4):557-9. doi: 10.2217/fon.14.268.
    • Letter, Editorial / Commentary
    • Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications.
    • Dubeau L.
    • Transl Cancer Res. 2015 Feb;4(1):3-13.
    • Olaparib Approved for Advanced Ovarian Cancer
    • [No author given]
    • Cancer Discovery. 2015 Jan 23. [Epub ahead of print]. doi: 10.1158/2159-8290.CD-NB2015-011
    • Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    • Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM.
    • J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.

    Comment / Letter

    Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?

    Letter

    To BRCA or Not to PALB.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    Comment / Editorial

    The Long and Winding Road.

    Press: Olaparib Trial Offers a Look at Precision Medicine's Future. (Medscape Oncology)

    • Myriad Genetics' Tumor BRACAnalysis CDx Receives CE Mark
    • GenomeWeb staff reporter
    • GenomeWeb, 2015 Jan 8.
    • It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer.
    • Carlucci A, D'Angiolella V.
    • Br J Cancer. 2015 Jan 6;112(1):9-13. doi: 10.1038/bjc.2014.594. Epub 2014 Dec 9.
    • Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis.
    • Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT.
    • Clin Cancer Res. 2015 Jan 1;21(1):211-20. doi: 10.1158/1078-0432.CCR-14-1816. Epub 2014 Oct 27.

    Comment / Letter

    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Letter.

    Reply / Letter

    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Response.

    • Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors.
    • Lord CJ, Tutt AN, Ashworth A.
    • Annu Rev Med. [2015 Jan;]66:455-70. doi: 10.1146/annurev-med-050913-022545. Epub 2014 Oct 17.
    • Review
    • Olaparib effective in four advanced cancers.
    • [No authors listed]
    • Cancer Discov. 2015 Jan;5(1):OF3. doi: 10.1158/2159-8290.CD-NB2014-176. Epub 2014 Dec 9.
    • PARP Inhibition in Ovarian Cancer: State of the Science.
    • Gunderson CC, Moore KN.
    • Gynecol Oncol. 2015 Jan;136(1):8-10. doi: 10.1016/j.ygyno.2014.12.009.
    • Editorial / Commentary
    • PARP inhibitors in BRCA mutation-associated ovarian cancer.
    • Clamp A, Jayson G.
    • Lancet Oncol. 2015 Jan;16(1):10-2. doi: 10.1016/S1470-2045(14)71172-6. Epub 2014 Dec 4.
    • Comment
    • Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    • Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.
    • Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4.

    Comment

    PARP inhibitors in BRCA mutation-associated ovarian cancer.

    • An update on PARP inhibitors-moving to the adjuvant setting.
    • Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M.
    • Nat Rev Clin Oncol. 2015 Jan;12(1):27-41. doi: 10.1038/nrclinonc.2014.163. Epub 2014 Oct 7.
    • Review
    • Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
    • Duffy MJ, Walsh S, McDermott EW, Crown J.
    • Adv Clin Chem. 2015;71:1-23. doi: 10.1016/bs.acc.2015.05.001. Epub 2015 Jun 23.
    • Review

    Comment / Introductory Journal Article

    Preface.

    • Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    • Tan DS, Kaye SB.
    • Am Soc Clin Oncol Educ Book. 2015:114-21. doi: 10.14694/EdBook_AM.2015.35.114.
    • Advances in PARP inhibitors for the treatment of breast cancer.
    • Dizdar O, Arslan C, Altundag K.
    • Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20.
    • Review
    • FDA Approves First PARP Inhibitor with Myriad's BRACAnalysis as CDx in Advanced Ovarian Cancer.
    • Turna Ray.
    • GenomeWeb, 2014 Dec 23.
    • A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.
    • Nicum S, Roberts C, Boyle L, Kopijasz S, Gourley C, Hall M, Montes A, Poole C, Collins L, Schuh A, Dutton SJ; 6MP Collaborative Group.
    • BMC Cancer. 2014 Dec 19;14(1):983. doi: 10.1186/1471-2407-14-983.
    • FDA Approves Myriad's BRACAnalysis CDx for Use with Ovarian Cancer Drug.
    • GenomeWeb staff reporter.
    • GenomeWeb, 2014 Dec 19.
    • FDA Approves Olaparib (Lynparza) for BRCA Ovarian Cancer.
    • Zosia Chustecka.
    • Medscape Oncology, 2014 Dec 19.
    • Olaparib Approved in Europe for BRCA Ovarian Cancer.
    • Chustecka Z.
    • Medscape. 2014 Dec 18.
    • Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    • Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS.
    • Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x.
    • A Genomic Instability Score in Discriminating Nonequivalent Outcomes of BRCA1/2 Mutations and in Predicting Outcomes of Ovarian Cancer Treated with Platinum-Based Chemotherapy.
    • Zhang S, Yuan Y, Hao D.
    • PLoS One. 2014 Dec 1;9(12):e113169. doi: 10.1371/journal.pone.0113169. eCollection 2014.
    • Myriad, AbbVie Expand Tumor BRACAnalysis CDx Collaboration.
    • [No author given]
    • Clinical OMICs. 1(14):5. 2014 Nov 19.
    • Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study.
    • Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, Matceyevsky D, Weizman A, Klausner JM.
    • J Surg Oncol. 2014 Nov;110(6):661-5. doi: 10.1002/jso.23688. Epub 2014 Jun 24.
    • European OK for Olaparib in Ovarian Cancer.
    • Chustecka Z.
    • Medscape. 2014 Oct 24.
    • BRCA1/2 Mutation Status Is an Independent Factor of Improved Survival for Advanced (Stage III-IV) Ovarian Cancer.
    • Rudaitis V, Zvirblis T, Kanopiene D, Janulynaite D, Griskevicius L, Janavicius R.
    • Int J Gynecol Cancer. 2014 Oct;24(8):1395-400. doi: 10.1097/IGC.0000000000000247.
    • Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
    • Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA.
    • Lancet Oncol. 2014 Oct;15(11):1207-14. doi: 10.1016/S1470-2045(14)70391-2. Epub 2014 Sep 10.
    • Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation.
    • Moiseyenko VM, Chubenko VA, Moiseyenko FV, Zhabina AS, Gorodnova TV, Komarov YI, Bogdanov AA, Sokolenko AP, Imyanitov EN.
    • Med Oncol. 2014 Oct;31(10):199. doi: 10.1007/s12032-014-0199-x. Epub 2014 Sep 4.
    • Maintenance therapy in ovarian cancer.
    • Khalique S, Hook JM, Ledermann JA.
    • Curr Opin Oncol. 2014 Sep;26(5):521-8. doi: 10.1097/CCO.0000000000000110.
    • Review
    • PARP inhibition and synthetic lethality in ovarian cancer.
    • Eskander RN, Tewari KS.
    • Expert Rev Clin Pharmacol. 2014 Sep;7(5):613-22. doi: 10.1586/17512433.2014.930662. Epub 2014 Jul 2.
    • Review
    • Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers.
    • Yamamoto KN, Hirota K, Takeda S, Haeno H.
    • PLoS One. 2014 Aug 26;9(8):e105724. doi: 10.1371/journal.pone.0105724. eCollection 2014.
    • Myriad Awaits BRACAnalysis CDx Approval as it Works to Move Hereditary Cancer Testing to MyRisk
    • Molika Ashford
    • GenomeWeb, 2014 Aug 13
    • News
    • Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
    • Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R, Gianni L.
    • Br J Cancer. 2014 Aug 12;111(4):651-9. doi: 10.1038/bjc.2014.345. Epub 2014 Jul 15.
    • Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.
    • Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, Baselga J, Garber JE.
    • Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.
    • An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.
    • Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN.
    • Gynecol Oncol. 2014 Aug;134(2):331-7. doi: 10.1016/j.ygyno.2014.05.009. Epub 2014 May 15.
    • Made-to-measure medicine: BRCA and gynaecological cancer.
    • Foulkes WD.
    • Lancet Oncol. 2014 Jul;15(8):783-5. doi: 10.1016/S1470-2045(14)70246-3. Epub 2014 May 31.
    • Commentary
    • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
    • Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U.
    • Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31.
    • FDA Panel Votes Against Accelerated Approval for Olaparib.
    • Hand L.
    • Medscape. 2014 Jun 26.
    • Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    • Watkins JA, Irshad S, Grigoriadis A, Tutt AN.
    • Breast Cancer Res. 2014 Jun 3;16(3):211. doi: 10.1186/bcr3670.
    • Targeted Drug Combo Improves Outcomes in Ovarian Cancer.
    • Nelson R.
    • Medscape. 2014 Jun 1.
    • The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1- deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
    • Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, Rubin S, Gimotty P, Adams S.
    • Gynecol Oncol. 2014 Jun;133(3):584-590. doi: 10.1016/j.ygyno.2014.03.565. Epub 2014 Mar 27.
    • Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    • Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB.
    • Gynecol Oncol. 2014 Jun;133(3):591-8. doi: 10.1016/j.ygyno.2014.03.557. Epub 2014 Mar 20.
    • Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    • Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D.
    • Gynecol Oncol. 2014 Jun;133(3):599-606. doi: 10.1016/j.ygyno.2014.03.007. Epub 2014 Mar 11.
    • Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.
    • Sun CK, Zhang F, Xiang T, Chen Q, Pandita TK, Huang Y, Hu MC, Yang Q.
    • Oncotarget. 2014 May 30;5(10):3375-85.
    • Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses.
    • Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC.
    • J Natl Cancer Inst. 2014 May 19;106(6). pii: dju089. doi: 10.1093/jnci/dju089. Print 2014 Jun.
    • On the road to PARPi-platin.
    • Bookman MA.
    • J Natl Cancer Inst. 2014 May 19;106(6):dju119. doi: 10.1093/jnci/dju119. Print 2014 Jun.
    • What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer.
    • Thomas Herzog, Elizabeth M. Swisher, Kristin K. Zorn.
    • Medscape Education Oncology, 2014 May 6.
    • [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
    • Gaziev AI.
    • Radiats Biol Radioecol. 2014 May-Jun;54(3):229-40.
    • [Article in Russian]
    • Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
    • Kwa M, Edwards S, Downey A, Reich E, Wallach R, Curtin J, Muggia F.
    • Ann Surg Oncol. 2014 May;21(5):1468-73. doi: 10.1245/s10434-013-3277-y. Epub 2013 Oct 1.
    • PARP inhibitors in ovarian cancer: Current status and future promise.
    • Liu JF, Konstantinopoulos PA, Matulonis UA.
    • Gynecol Oncol. 2014 May;133(2):362-369. doi: 10.1016/j.ygyno.2014.02.039. Epub 2014 Mar 4.
    • Review
    • Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
    • Joshi PM, Sutor SL, Huntoon CJ, Karnitz LM.
    • J Biol Chem. 2014 Mar 28;289(13):9247-53. doi: 10.1074/jbc.M114.551143. Epub 2014 Feb 19.
    • Veliparib Active in BRCA-Positive Ovarian Cancer.
    • Fran Lowry.
    • Medscape Medical News from the Society of Gynecologic Oncology (SGO) 45th Annual Meeting on Women's Cancer, 2014 Mar 26.
    • Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.
    • Wiedemeyer WR, Beach JA, Karlan BY.
    • Front Oncol. 2014 Mar 3;4:34. doi: 10.3389/fonc.2014.00034. eCollection 2014.
    • Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.
    • Lin ZP, Ratner ES, Whicker ME, Lee Y, Sartorelli AC.
    • Mol Cancer Res. 2014 Mar;12(3):381-93. doi: 10.1158/1541-7786.MCR-13-0480. Epub 2014 Jan 10.
    • Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
    • O'Sullivan CC, Moon DH, Kohn EC, Lee JM.
    • Front Oncol. 2014 Feb 28;4:42. eCollection 2014.
    • BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.
    • Burgess M, Puhalla S.
    • Front Oncol. 2014 Feb 27;4:19. eCollection 2014.
    • Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
    • Bouwman P, Jonkers J.
    • Clin Cancer Res. 2014 Feb 1;20(3):540-7. doi: 10.1158/1078-0432.CCR-13-0225. Epub 2013 Nov 22.
    • Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
    • Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM.
    • Clin Cancer Res. 2014 Feb 1;20(3):764-75. doi: 10.1158/1078-0432.CCR-13-2287. Epub 2013 Nov 15.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: PALB2 and Ovarian Cancer

    Comment, Letter

    DNA repair mutations and outcomes in ovarian cancer--letter.

    Reply, Letter

    DNA repair mutations and outcomes in ovarian cancer--response.

    • 'BRCAness' and its implications for platinum action in gynecologic cancer.
    • Muggia F, Safra T.
    • Anticancer Res. 2014 Feb;34(2):551-6.
    • PARP inhibitors for anticancer therapy.
    • Curtin N.
    • Biochem Soc Trans. 2014 Feb;42(1):82-8. doi: 10.1042/BST20130187.
    • [Hereditary ovarian carcinomas: clinico-biological features and treatment].
    • Floquet A, Stoeckle E, Croce S, Longy M, Mc Grogan G, Barouk E, Bubien V, Garbay D, Joly E, Guyon F.
    • Bull Cancer. 2014 Feb;101(2):167-74. doi: 10.1684/bdc.2014.1888.
    • Review, [Article in French]
    • Natural and glucosyl flavonoids inhibit poly(ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells.
    • Maeda J, Roybal EJ, Brents CA, Uesaka M, Aizawa Y, Kato TA.
    • Oncol Rep. 2014 Feb;31(2):551-6. doi: 10.3892/or.2013.2902. Epub 2013 Dec 5.
    • Poly (ADP-ribose) polymerase 1 transcriptional regulation: a novel crosstalk between histone modification H3K9ac and ETS1 motif hypomethylation in BRCA1-mutated ovarian cancer.
    • Li D, Bi FF, Cao JM, Cao C, Li CY, Liu B, Yang Q.
    • Oncotarget. 2014 Jan 15;5(1):291-7.
    • Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity.
    • Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A.
    • Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15.
    • PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
    • Lee JM, Ledermann JA, Kohn EC.
    • Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12.
    • BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective.
    • Foulkes W.
    • Clin Genet. 2014 Jan;85(1):1-4. doi: 10.1111/cge.12291. Epub 2013 Oct 25.
    • Editorial / Commentary
    • Targeting the BRCA1/2 Tumor Suppressors.
    • Rosen EM, Pishvaian MJ.
    • Curr Drug Targets. 2014 Jan;15(1):17-31.
    • Review
    • Clinical implications of using molecular diagnostics for ovarian cancers.
    • Kohn EC, Romano S, Lee JM.
    • Ann Oncol. 2013 Dec;24 Suppl 10:x22-26. doi: 10.1093/annonc/mdt464.
    • Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.
    • Curtin NJ, Szabo C.
    • Mol Aspects Med. 2013 Dec;34(6):1217-56. doi: 10.1016/j.mam.2013.01.006. Epub 2013 Jan 29.
    • Appraising iniparib, the PARP inhibitor that never was--what must we learn?
    • Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS.
    • Nat Rev Clin Oncol. 2013 Dec;10(12):688-96. doi: 10.1038/nrclinonc.2013.177. Epub 2013 Oct 15.
    • Review
    • Synthetic lethality between CCNE1 amplification and loss of BRCA1.
    • Etemadmoghadam D, Weir BA, Au-Yeung G, Alsop K, Mitchell G, George J; Australian Ovarian Cancer Study Group, Davis S, D'Andrea AD, Simpson K, Hahn WC, Bowtell DD.
    • Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19489-94. doi: 10.1073/pnas.1314302110. Epub 2013 Nov 11.
    • miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition.
    • Sun C, Li N, Yang Z, Zhou B, He Y, Weng D, Fang Y, Wu P, Chen P, Yang X, Ma D, Zhou J, Chen G.
    • J Natl Cancer Inst. 2013 Nov 20;105(22):1750-8. doi: 10.1093/jnci/djt302. Epub 2013 Oct 29.
    • PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets.
    • Shah GM, Robu M, Purohit NK, Rajawat J, Tentori L, Graziani G.
    • Front Oncol. 2013 Nov 14;3:279. doi: 10.3389/fonc.2013.00279. eCollection 2013.
    • Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
    • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.
    • PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.
    • BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
    • Pothuri B.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii22-viii27. doi: 10.1093/annonc/mdt307.
    • Mechanisms of resistance to therapies targeting BRCA-mutant cancers.
    • Lord CJ, Ashworth A.
    • Nat Med. 2013 Nov;19(11):1381-8. doi: 10.1038/nm.3369. Epub 2013 Oct 7.
    • Review
    • Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
    • Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI.
    • Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-17046. Epub 2013 Oct 1.
    • Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
    • Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB.
    • Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6.
    • The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.
    • Reinbolt RE, Hays JL.
    • Front Oncol. 2013 Oct 1;3:237. doi: 10.3389/fonc.2013.00237.
    • Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.
    • Shaw HM, Hall M.
    • Onco Targets Ther. 2013 Sep 3;6:1197-206. doi: 10.2147/OTT.S30748.
    • A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
    • Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA.
    • Eur J Cancer. 2013 Sep;49(14):2972-8. doi: 10.1016/j.ejca.2013.05.020. Epub 2013 Jun 27.
    • Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
    • Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.
    • Br J Cancer. 2013 Aug 20;109(4):1072-8. doi: 10.1038/bjc.2013.389. Epub 2013 Jul 18.
    • Olaparib: a promising PARP inhibitor in ovarian cancer therapy.
    • Chen Y, Zhang L, Hao Q.
    • Arch Gynecol Obstet. 2013 Aug;288(2):367-74. doi: 10.1007/s00404-013-2856-2. Epub 2013 Apr 26.
    • Review
    • Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
    • Gan A, Green AR, Nolan CC, Martin S, Deen S.
    • Hum Pathol. 2013 Aug;44(8):1638-47. doi: 10.1016/j.humpath.2013.01.015. Epub 2013 Apr 8.
    • The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    • Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM.
    • Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28.

    Commentary:

    PARP inhibitors: pitfalls and promises.

    • Inhibition of DNA damage repair by artificial activation of PARP with siDNA.
    • Croset A, Cordelières FP, Berthault N, Buhler C, Sun JS, Quanz M, Dutreix M.
    • Nucleic Acids Res. 2013 Aug;41(15):7344-55. doi: 10.1093/nar/gkt522. Epub 2013 Jun 12.
    • RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.
    • Lok BH, Carley AC, Tchang B, Powell SN.
    • Oncogene. 2013 Jul 25;32(30):3552-8. doi: 10.1038/onc.2012.391. Epub 2012 Sep 10.
    • Olaparib shows promise in multiple tumor types.
    • [No authors listed]
    • Cancer Discov. 2013 Jul;3(7):OF5. doi: 10.1158/2159-8290.CD-NB2013-082. Epub 2013 Jun 6.
    • Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
    • Galic V, Coleman RL, Herzog TJ.
    • Curr Cancer Drug Targets. 2013 Jul;13(6):698-707.
    • Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O/AZD2281) in combination with carboplatin (C) in ovarian cancer (OvCa) patients with BRCA1/2 mutations (OvCaMUT +) and high grade serous OvCa (HGSOC) with low genetic risk (NCT00647062).
    • Lee J, Hays J, Noonan A, Annunziata C, Minasian L, Zujewski J, Houston N, Hearn J, Yu M, Kohn E.
    • Gynecologic Oncology. 2013 Jul;130(1):e11. 44th Annual Meeting of the Society of Gynecologic Oncology. doi: 10.1016/j.ygyno.2013.04.083.
    • Conference abstract
    • PARP Inhibitor Research Update.
    • Susan Domchek.
    • FORCE. Be Empowered Webinars. 2013 Jun 27.
    • BRCA1 reversion mutation acquired after treatment identified by liquid biopsy.
    • Mayor P, Gay LM, Lele S, Elvin JA.
    • Gynecol Oncol Rep. 2017 Jun 21;21:57-60. doi: 10.1016/j.gore.2017.06.010. eCollection 2017 Aug.
    • ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status.
    • Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM.
    • Cancer Res. 2013 Jun 15;73(12):3683-91. doi: 10.1158/0008-5472.CAN-13-0110. Epub 2013 Apr 2.
    • Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    • Secord AA, Barnett JC, Ledermann JA, Peterson BL, Myers ER, Havrilesky LJ.
    • Int J Gynecol Cancer. 2013 Jun;23(5):846-52. doi: 10.1097/IGC.0b013e31829527bd.
    • Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
    • Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE.
    • Mol Cancer Ther. 2013 Jun;12(6):1002-15. doi: 10.1158/1535-7163.MCT-12-0813. Epub 2013 May 31.
    • BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
    • Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT.
    • Mol Oncol. 2013 Jun;7(3):567-79. doi: 10.1016/j.molonc.2012.12.007. Epub 2013 Jan 31.
    • BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
    • Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC.
    • Br J Cancer. 2013 Apr 2;108(6):1231-7. doi: 10.1038/bjc.2013.70. Epub 2013 Mar 5.

    Research news: Can BRCA Expression Predict Response to Chemotherapy? (Medscape)

    • Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.
    • Tan DS, Yap TA, Hutka M, Roxburgh P, Ang J, Banerjee S, Grzybowska E, Gourley C, Gore ME, Kaye SB.
    • Eur J Cancer. 2013 Apr;49(6):1246-53. doi: 10.1016/j.ejca.2012.11.016. Epub 2012 Dec 19.
    • Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer.
    • Bi FF, Li D, Yang Q.
    • BMC Cancer. 2013 Feb 26;13:90. doi: 10.1186/1471-2407-13-90.
    • Genetics of Susceptibility to Sporadic Ovarian Cancer.
    • Katabathina VS, Prasad SR.
    • eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net. doi: 10.1002/9780470015902.a0023853. 2013 Feb.
    • Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation.
    • Wong HH, Parkinson C, Ledermann JA, Brenton JD, Merger M, Shaw A, Patterson A, Shafi M, Earl HM.
    • Gynecol Oncol Case Rep. 2013 Jan 1;3:7-10. doi: 10.1016/j.gynor.2012.10.003.
    • Major clinical research advances in gynecologic cancer in 2012.
    • Suh DH, Kim JW, Kim K, Kim HJ, Lee KH.
    • J Gynecol Oncol. 2013 Jan;24(1):66-82. doi: 10.3802/jgo.2013.24.1.66. Epub 2013 Jan 8.
    • Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options.
    • Elit L, Hirte H.
    • Onco Targets Ther. 2013;6:107-18. doi: 10.2147/OTT.S30238. Epub 2013 Feb 26.
    • Mitochondrial DNA mutation in serous ovarian cancer: implications for mitochondria-coded genes in chemoresistance.
    • Guerra F, Perrone AM, Kurelac I, Santini D, Ceccarelli C, Cricca M, Zamagni C, De Iaco P, Gasparre G.
    • J Clin Oncol. 2012 Dec 20;30(36):e373-8. doi: 10.1200/JCO.2012.43.5933. Epub 2012 Nov 13.
    • PARP Inhibitors: Targeting the Right Patients.
    • Azvolinsky A.
    • J Natl Cancer Inst. 2012 Dec 19;104(24):1851-2. doi: 10.1093/jnci/djs514. Epub 2012 Dec 10.
    • Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
    • Mukhopadhyay A, Plummer ER, Elattar A, Soohoo S, Uzir B, Quinn JE, McCluggage WG, Maxwell P, Aneke H, Curtin NJ, Edmondson RJ.
    • Cancer Res. 2012 Nov 15;72(22):5675-82. doi: 10.1158/0008-5472.CAN-12-0324. Epub 2012 Oct 11.
    • Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
    • Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, Fitzgerald LM, Krivak T, Deloia JA, Gutin A, Mills GB, Lanchbury JS.
    • Br J Cancer. 2012 Nov 6;107(10):1776-82. doi: 10.1038/bjc.2012.451. Epub 2012 Oct 9.
    • BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
    • Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M.
    • Epigenetics. 2012 Nov;7(11):1225-9. doi: 10.4161/epi.22561. Epub 2012 Oct 15.
    • Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    • Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.
    • Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

    Comment:

    Addicted to PAR? A closer look at PARP inhibitor sensitivity.

    Comment:

    Predicting PARP inhibitor sensitivity and resistance.

    • Olaparib , PARP1 inhibitor in ovarian cancer.
    • Marchetti C, Imperiale L, Gasparri ML, Palaia I, Pignata S, Boni T, Bellati F, Benedetti Panici P.
    • Expert Opin Investig Drugs. 2012 Oct;21(10):1575-84. Epub 2012 Jul 13.
    • Review
    • Molecular-targeted therapies for ovarian cancer: prospects for the future.
    • Sudo T.
    • Int J Clin Oncol. 2012 Oct;17(5):424-9. doi: 10.1007/s10147-012-0461-1. Epub 2012 Aug 23.
    • Review
    • Identification of DNA Repair Pathways That Affect the Survival of Ovarian Cancer Cells Treated with a Poly(ADP-Ribose) Polymerase Inhibitor in a Novel Drug Combination.
    • Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM.
    • Mol Pharmacol. 2012 Oct;82(4):767-76. Epub 2012 Jul 25.
    • Lack of BRCA testing approval creates snag for cancer trials.
    • Azvolinsky A.
    • Nat Med. 2012 Sep 7;18(9):1310. doi: 10.1038/nm0912-1310a.
    • News
    • Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
    • Ratner ES, Sartorelli AC, Lin ZP.
    • Curr Opin Oncol. 2012 Sep;24(5):564-71. doi: 10.1097/CCO.0b013e3283564230.
    • Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.
    • Stecklein SR, Jensen RA.
    • Transl Res. 2012 Sep;160(3):178-97. doi: 10.1016/j.trsl.2012.01.022. Epub 2012 Feb 9.
    • Review
    • BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.
    • Stecklein SR, Kumaraswamy E, Behbod F, Wang W, Chaguturu V, Harlan-Williams LM, Jensen RA.
    • Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13650-5. doi: 10.1073/pnas.1203326109. Epub 2012 Aug 6.
    • Cancer treatment according to BRCA1 and BRCA2 mutations.
    • Maxwell KN, Domchek SM.
    • Nat Rev Clin Oncol. 2012 Aug 14;9(9):520-8. doi: 10.1038/nrclinonc.2012.123. Epub 2012 Jul 24.
    • Review
    • Olaparib in platinum-sensitive ovarian cancer.
    • Kaji D, Miura Y, Takano T.
    • N Engl J Med. 2012 Jul 12;367(2):179; author reply 179-80. doi: 10.1056/NEJMc1205423#SA1.
    • Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ.
    • Warrener P, Kim S, Williams SM, Biery M, Gordon M, Toniatti C, Cleary MA, Linsley PS, Carleton M.
    • Apoptosis. 2012 Jul;17(7):691-701. doi: 10.1007/s10495-012-0707-4.
    • HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells.
    • Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P, Hideg K, Selvendiran K.
    • Cancer Biol Ther. 2012 Jul;13(9):766-75. doi: 10.4161/cbt.20559.
    • [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
    • Kluzek K, Białkowska A, Koczorowska A, Zdzienicka MZ.
    • Postepy Hig Med Dosw (Online). 2012 Jun 15;66:372-84.
    • BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    • Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD 2nd, Lanchbury JS, Krivak TC.
    • Gynecol Oncol. 2012 Jun;125(3):677-82. doi: 10.1016/j.ygyno.2012.03.006. Epub 2012 Mar 8.
    • [PARP inhibitors--theoretical basis and clinical application].
    • Dębska S, Kubicka J, Czyżykowski R, Habib M, Potemski P.
    • Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21.
    • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
    • Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U.
    • N Engl J Med. 2012 Apr 12;366(15):1382-92. doi: 10.1056/NEJMoa1105535. Epub 2012 Mar 27.

    Comment, Letter:

    Olaparib in platinum-sensitive ovarian cancer.

    • Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
    • Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL.
    • Cancer Discov. 2012 Apr;2(4):366-75. doi: 10.1158/2159-8290.CD-11-0206. Epub 2012 Mar 22.
    • A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
    • Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH.
    • Clin Cancer Res. 2012 Mar 15;18(6):1726-34. doi: 10.1158/1078-0432.CCR-11-2821. Epub 2012 Feb 3.
    • Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
    • Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM, Friedlander M, Safra T, Vergote I, Wickens M, Lowe ES, Carmichael J, Kaufman B.
    • J Clin Oncol. 2012 Feb 1;30(4):372-9. doi: 10.1200/JCO.2011.36.9215. Epub 2011 Dec 27.

    Comment, Editorial:

    Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial.

    • Hereditary ovarian cancer: Beyond the usual suspects.
    • Pennington KP, Swisher EM.
    • Gynecol Oncol. 2012 Feb;124(2):347-53. doi: 10.1016/j.ygyno.2011.12.415.
    • Review
    • PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check.
    • Zorn KK.
    • Oncology (Williston Park). 2012 Feb;26(2):128-36.

    Comment:

    The maze of PARP inhibitors in ovarian cancer.

    Comment:

    The circuitous path of PARP inhibitor development in epithelial ovarian cancer.

    • Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases.
    • Melichar B, Laco J, Fridrichová P, Simkovič M, Papajík T, Foretová L.
    • Acta Oncol. 2012 Jan;51(1):136-8. Epub 2011 Aug 22.
    • Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
    • Vollebergh MA, Jonkers J, Linn SC.
    • Cell Mol Life Sci. 2012 Jan;69(2):223-45. doi: 10.1007/s00018-011-0809-0. Epub 2011 Sep 16.
    • Review
    • Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals.
    • Chen SS, Michael A, Butler-Manuel SA.
    • Discov Med. 2012 Jan;13(68):7-17.
    • Biologicals in the upfront treatment of ovarian cancer: focus on bevacizumab and poly (adp-ribose) polymerase inhibitors.
    • Roux R, Zweifel M, Rustin GJ.
    • Am Soc Clin Oncol Educ Book. 2012:340-4. doi: 10.14694/EdBook_AM.2012.32.340.
    • The role of PARP inhibitors in the treatment of ovarian carcinomas.
    • Tinker AV, Gelmon K.
    • Curr Pharm Des. 2012;18(25):3770-4.
    • Review